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ABSTRACT: Combining the desymmetrization of a prochiral bis-hydroxymethyl group with 
the epimerization of a chiral furanyl ether in a single transformation, high levels of double 
diastereoselectivity have been achieved in a synthesis of 2,4,5-trisubstituted tetrahydropyrans 
which proceeds under thermodynamic control.   
 
 
Introduction 
The tetrahydropyran moiety is found in a large number of biologically active natural and non-
natural products and can rightly be classed as a privileged scaffold.
1
 Examples include 
zincophorin (ionophore antibiotic)
1a
, sorangicin-A (antibiotic)
1b
, polycarvernoside-A (algal 
toxin)
1c
, the bryostatins (cytotoxins)
1d,e
, salinomycin (coccidiostat ionophore)
1f,g
, 
halichondrin-B (cytotoxin)
1h
, eribulin (simplified synthetic analogue of halichondrin-B and 
clinical cancer chemotherapeutic)
1i
, swinholide-A (actin-binding cytotoxin)
1j
 and the 
tubulexins (modulators of mitosis)
1k
. Due to the importance of these and other compounds, 
the development of new stereoselective methodologies for tetrahydropyran construction has 
been, and continues to be, the focus of intense research activity.
2
 Building on our previous 
research into the use of epimerizable furanyl ethers in cyclic scaffolds,
3
 we here report the 
diastereoselective formation of 2,4-syn-disubstituted tetrahydropyrans and the doubly 
diastereoselective formation of 2,4,5-syn,anti-trisubstituted tetrahydropyrans. Our conceptual 
plan is outlined in Scheme 1.  
 
Scheme 1: Conceptual Outline 
 
 
Using the ability of 2-furanyl ethers to epimerize under acidic conditions (via furanyl cations, 
2),
4
 we reasoned that a suitably placed substituent at the 4 position of a tetrahydropyran 
formed through the reversible cyclization of either diastereisomer of diol 1 would favor 
formation of the 2,4-syn product syn-3. This would place both the 4-substituent and the 
furanyl group in favored equatorial positions on a chair conformation. Each diastereisomer of 
diol 1, present as a diastereisomeric mixture, would thus be converted to the same product 
diastereisomer, irrespective of the original C-2/C-4 stereochemical relationship. Building on 
this basic idea, the inclusion of a second hydroxymethyl group at C-5 would provide a 
prochiral bis(hydroxymethyl) center in 4 that would undergo desymmetrization
5
 upon 
cyclization by the same reversible mechanism. The primary alcohol selected for inclusion in 
the tetrahydropyran ring would be such that the remaining uncyclized hydroxymethyl group 
at C-5 was left in an equatorial position. 
Under thermodynamic conditions, syn-anti-5, in which all substituents are in 
equatorial positions, would accordingly be favored. The chiral center at C-4 would thus 
control the configuration at both C-2 and C-5 (Scheme 1). In addition to facilitating the key 
cyclization/epimerization mechanism, the furan moiety is also synthetically versatile and can 
be converted into a number of useful functional motifs (e.g. oxidative cleavage to the 
carboxylic acid
6a
, Achmatowicz-type oxidations
6b
, hydrogenation
6c
 to the tetrahydrofuran, 
Diels-Alder cycloadditions
6d
, [4+3] cycloadditions
6e
 etc).  
 
Results and Discussion 
Scheme 2: Synthetic Route to Diol and Triol Substrates 
 
 
 
 
Our investigation began with the synthesis of diol substrates 1a-k (Scheme 2). Claisen-
Schmidt aldol condensation of either 2-acetylfuran 6a or 5-methyl-2-acetyl furan 6b with a 
series of substituted benzaldehydes (which avoid self-aldol condensation) afforded the enones 
7a-k, from which Michael addition of dimethylmalonate furnished the keto-diesters 8a-k. 
Subsequent Krapcho decarboxylation led to the ketoesters 9a-k, which were purified by 
column chromatography. LiAlH4 reduction provided the diols 1a-k (formed as approximately 
1:1 diastereisomeric mixtures) which were used without chromatographic purification.  
 
Table 1: Diol Cyclization Results.  
 
 
 
Entry         Ar R Diol (d.r.) Yld Prod (d.r.) 
1 C6H5 H 1a (1:0.7) 76 % 3a (16:1) 
2 4-C6H4-Cl H 1b (1:0.75) 80 % 3b (21:1) 
3 4-C6H4-Cl H 1b (4:1) 76 % 3b (19:1) 
4 4-C6H4-Cl H 1b (1:6) 78 % 3b (20:1) 
5 4-C6H4-OMe H 1c (1:0.75) 60 % 3c (11:1) 
6 4-C6H3-Me H 1d (1:0.74) 83 % 3d (20:1) 
7 3,4-C6H3-(OMe)2 H 1e (1:0.8) 95 % 3e (20:1) 
8 4-C6H4-Br H 1f (1:0.76) 96 % 3f (12:1) 
9 2,4,5-C6H2-(OMe)3 H 1g (1:0.65) 93 % 3g (25:1) 
10 4-C6H4-Br Me 1h (1:0.67) 70 % 3h (21:1) 
11 C6H5 Me 1i (1:0.65) 88 % 3i (18:1) 
12 4-C6H4-CH3 Me 1j (1:0.7) 86 % 3j (19:1) 
13 4-C6H4-Cl Me 1k (1:0.75) 68 % 3k (20:1) 
 
With these diols in hand we investigated their acid catalyzed cyclizations. A brief screen of 
solvents and acids identified acetonitrile and polymer supported sulfonic acid as satisfactory, 
combining clean and rapid cyclization/epimerization with ease of workup (Table 1). Initial 
investigation focused on phenyl substrate 1a. The cyclization reaction itself was relatively 
rapid. Loss of starting material was almost complete after 10 minutes (as judged by TLC and 
NMR analysis of an aliquot). The initial ratio of syn and anti diastereomers syn-3a and anti-
3a at this time was 2.2:1. After 10 hours, a diastereomeric ratio of 16:1 was obtained. 
Analysis of chemical shifts, coupling constants and NOESY correlations in the 
1
H NMR 
spectra indicated that the major product was the syn-3a diastereomer. Using the same 
conditions, the cyclization reaction was carried out on a series of diol substrates 1a-k to 
afford the 2,4-syn tetrahydropyran products 3a-k in high yields and with diastereoselectivities 
ranging from 11:1 to 25:1 (Table 1). Adventitiously, we found that careful chromatography of 
para-chloro diol 1b afforded diastereomerically enriched samples, both of which cyclized to 
essentially the same ratio of tetrahydropyran diastereisomers as the original 1:0.75 mixture 
(Table 1, entries 2-4). Pleasingly, tetrahydropyrans syn-3e and syn-3g formed crystals from 
which we were able to obtain X-ray structures, confirming the stereochemistry (Figure 1, 
syn-3g structure in Supp Info.) To explore our mechanistic hypothesis, and to obtain more of 
the minor diastereisomer for NMR analysis, we carried out the cyclization under base 
mediated conditions (Scheme 3). Treatment of the 1:0.7 syn/anti diastereisomeric mixture of 
diols 1a with NaH and toluenesulfonyl chloride led to the formation of tetrahydropyrans syn-
3a and anti-3a in the same 1:0.7 diastereomeric ratio, presumably via 10. 
 
Scheme 3: Base Promoted Cyclization (Avoiding Epimerization).  
 
It is therefore unlikely that stereochemical equilibration at the furanyl center occurs under 
these basic conditions. Syn-3a and anti-3a could be separated (at length) by careful column 
chromatography. The 2,4-anti diastereomer had an identical 
1
H NMR spectrum to the minor 
component from the acid catalyzed cyclization. The isolated anti-3a, when exposed to the 
polymer supported sulfonic acid resin in acetonitrile, was cleanly converted to syn-3a, 
consistent with the proposed mechanism. Having established that the C-4 substituent could 
exert control of the configuration at C-2, we next investigated simultaneous control over the 2 
and 5 positions. 
 
Figure 1. X-Ray Structure of syn-3e (Thermal Ellipsoids Drawn at 50%) 
 
 
 
 
 
 
LiAlH4 reduction of ketodiesters 8a-k afforded triols 4a-k (Scheme 2). Using the same acidic 
conditions established for the diol substrates, cyclization of triol 4a (d.r.=1:0.8) proceeded 
smoothly and, after equilibration, the product 5a was formed in high yield and with high 
diastereoselectivity. The two major diastereomers were formed in a ratio of 26:1. Similar 
results were also obtained for a number of other triol substrates, present as approximately 1:1 
mixtures of diastereomers (Table 2). In each case, key NMR signals for major and minor 
diastereomers closely mirrored those of 5a. 
1
H NMR coupling constants, chemical shifts and 
NOESY correlations were consistent with the major products having 2,4,5-syn,anti 
stereochemistry with all substituents in equatorial positions, as predicted. This was confirmed 
by single crystal X-ray analysis of syn,anti-5g (Figure 2). The main observable minor 
diastereomer had a significantly higher chemical shift for the C-2 hydrogen, consistent with 
an equatorial orientation, indicating that this diastereomer was epimeric at the furanyl ether 
center. Although the reaction was clearly very diastereoselective, we sought clarity as to the 
nature and distribution of all minor diastereomers (several NMR peaks of which were 
dwarfed and obscured by those of the major product).  
 
Table 2. Triol Cyclization Results.   
 
 
Entry        Ar R Triol (d.r.) Yld Prod (d.r.) 
1 C6H5 H 4a (1:0.8) 99% 5a (26:1) 
2 4-C6H4-Cl H 4b (1:0.8) 95% 5b (21:1) 
3 4-C6H4-Cl H anti-4b  92% 5b (21:1) 
4 4-C6H4-Cl H syn-4b 94% 5b (21:1) 
5 4-C6H4-OMe H 4c (1:0.65) 87% 5c (20:1) 
6 4-C6H3-Me H 4d (1:0.75) 89% 5d (25:1) 
7 3,4-C6H3-(OMe)2 H 4e (1:1) 89% 5e (24:1) 
8 4-C6H4-Br H 4f (0.8:1) 86% 5f (20:1) 
9 2,4,5-C6H2-(OMe)3 H 4g (1:0.5) 96% 5g (20:1) 
10 4-C6H4-Br Me 4h (1:0.6) 63% 5h (19:1) 
11 C6H5 Me 4i (1:0.5) 84% 5i (20:1) 
12 4-C6H4-CH3 Me 4j (1:0.6) 75% 5j (21:1) 
13 4-C6H4-Cl Me 4k (1:0.6) 87% 5k (20:1) 
 
 
 
 
 
 
Figure 2. X-ray structure of 2,4,5-syn,anti-5g (thermal ellipsoids shown at 50%) 
 
 
 
 
 
 
 
Chromatographic isolation of minor diastereomers eluded our efforts. Fortuitously, we found 
that the anti diastereomer of the para-chloro triol compound, anti-4b, was crystalline whilst 
syn-4b was an oil. This discovery suggested a possible means of accessing all four possible 
cyclization products and, by comparison of spectra, of determining the product distribution 
obtained during the triol cyclization. At length, repeated cycles of recrystallization from ethyl 
acetate furnished useful quantities of the diastereomerically pure triols, anti-4b and syn-4b. 
In addition to facilitating this separation, the crystalline nature of anti-4b provided, through 
X-ray crystallography, unambiguous determination of its relative stereochemistry (and 
therefore the relative stereochemistry of syn-4b also), Figure 3.  
 
Figure 3. X-ray structure of Anti-4b (thermal ellipsoids at 50%) 
 
Consistent with the proposed mechanism, either of these pure triol diastereomers, when 
exposed to the cyclization conditions, furnished the same 21:1 ratio of products as obtained 
from cyclization of the original 1:0.8 mixture of diastereomers (Table 2, entries 3 and 4). 
Triols anti-4b and syn-4b could be converted to the corresponding mixtures of mono-TBDPS 
ethers 11a,b and 11c,d where, in each case, the TPDPS ether was formed at one of the two 
primary alcohols (Scheme 4). The pair of mono-TBDPS ethers, 11a and 11b, were separated 
from each other by careful column chromatography on silica gel, as were 11c and 11d. 
Following their isolation, each of these diastereomerically pure diols was then independently 
cyclized under the established acidic conditions. With one hydroxymethyl group now tied up 
as a TBDPS ether, epimerization of the bis(hydroxymethyl) group was no longer possible, 
thus fixing the C-4/C-5 relative stereochemistry. Epimerization was limited to the furanyl 
center at C-2. As expected, the stereochemistry at the configurationally labile furanyl center 
in the starting material had no bearing on the stereochemical outcome of the reaction. Each 
diol 11a-d produced only one of the two possible pairs of products (12a,b or 12c,d), 
depending only on the C-4/C-5 relative stereochemistry. Thus, 11a and 11c, whose relative 
stereochemistries differ only at the C-2 furanyl alcohol, both afforded the same mixture of 
tetrahydropyrans 12a,b, epimeric at C-2, in the same diastereomeric ratio. Likewise, when 
either 11b or 11d were cyclized, the same mixture of C-2 epimers 12c and 12d was formed. 
These cyclization reactions were left for only 3 hours in order to obtain observable NMR 
peaks for the minor products rather than attempt to achieve greater diastereoselectivity. In 
each pair, the 
1
H NMR spectrum of the major component was consistent with having an axial 
hydrogen at C-2. Once the TBDPS groups of the 12a,b and 12c,d mixtures were removed, 
using TBAF, the NMR spectra of the resulting mixtures of alcohols ([syn,anti-5b + anti,anti-
5b] from 12a,b and [syn,syn-5b + anti,syn-5b] from 12c,d)  were compared with that 
obtained following the cyclization of triol 4b. It was found that syn,anti-5b, anti,anti-5b, and 
syn,syn-5b were present in the triol cyclization product, in a ratio of 25:1:0.9, whilst the 
remaining diastereomer, anti,syn-5, was not present at all. Interestingly, cyclization of either 
11b or 11d to the mixture of products 12c,d was also diastereoselective (d.r. = 6:1, 
unoptimized). Once the restraining TPDPS group was removed from each pair of 
tetrahydropyrans, acid catalyzed equilibration of either [syn,syn-5b + anti,syn-5b] or 
[syn,anti-5b + anti,anti-5b] led cleanly to the same 25:1:0.9 mixture of diastereomers as 
obtained from cyclization of triol 4b (Scheme 4). 
 
Scheme 4. Stereochemical correlations 
 
 
In conclusion, the formation of 2,4-disubstituted tetrahydropyrans occurs via a highly 
diastereoselective acid mediated cyclization-epimerization reaction which favors the 2,4-syn 
diastereomer capable of adopting the energetically favorable diequatorial chair conformation. 
The reaction harnesses the propensity of the furanyl ether moiety to epimerize in the presence 
of a suitable acid catalyst, presumably via a furanyl cation intermediate. Extending the 
concept further, 2,4,5-trisubstituted tetrahydropyrans are also formed in a reaction which 
displays very high levels of double diastereoselectivity favoring the 2,4,5-syn,anti 
diastereomer.  
 
Experimental Section 
 
NMR spectra were recorded in CDCl3, CD3CN or CD3OD solutions at room temperature with 
a 400 MHz spectrometer (400 MHz for 
1
H, 100 MHz for 
13
C) or a 300 MHz spectrometer 
(300 MHz for 
1
H, 75 MHz for 
13
C). CDCl3 was stored over granular anhydrous potassium 
carbonate in a brown glass bottle. The 
1
H and 
13
C chemical shifts are reported relative to 
tetramethylsilane (0.0 ppm). Coupling constants (J-values) are reported in Hz. In a few 
instances, apodization was used to facilitate J-value determination. Protons coupling to two 
other non-identical protons but with identical coupling constants are generally referred to as 
doublets of doublets, rather than triplets (or apparent triplets). Assignment of peaks in the 
proton NMR spectra was carried out using chemical-shift values, coupling constants, COSY, 
TOCSY, HMBC and HSQC. Peak assignments given in the 
1
H NMR data follow the 
numbering scheme used for THP rings in the manuscript (see diagrams in Supporting 
Information for details). Melting point temperatures are uncorrected. TLC analysis was 
carried out using silica gel impregnated with fluorescent indicator on aluminium backed 
plates. Plates were visualized either by UV fluorescence (254 nm) or by staining with acidic 
vanillin solution or alkaline potassium permanganate solution. Column chromatography was 
carried out using silica gel. Where anhydrous tetrahydrofuran was required, this was either 
purchased in anhydrous form or was obtained by passing reagent grade unstabilized solvent 
through alumina packed columns under nitrogen (Grubbs system). Where anhydrous diethyl 
ether was required, this was obtained by stirring reagent grade diethyl ether with calcium 
hydride under a nitrogen atmosphere. All other solvents were used as supplied without further 
purification. HRMS measurements were carried out on an LCMS mass spectrometer using 
electrospray ionization and a TOF analyzer. Infrared spectra were obtained using a thin film 
(evaporated from solution) on an ATR spectrometer. Single-crystal X-ray diffraction analyses 
of 3e, 3g, anti-4b and 5g were performed using an area detector mounted at the window of a 
rotating anode generator with a Mo anode (λ=0.71075Å) and equipped with a cryostream 
device. The crystals were mounted on  loops and the data were collected at 100 K. Data were 
processed and empirical absorption corrections were carried out using CrystalClear SM-
Expert.
7
 The structures were solved by charge-flipping using SUPERFLIP
8
 and refined on Fo
2
 
by full-matrix least squares refinement using SHELXL-2014.
9
 All non-hydrogen atoms were 
refined with anisotropic displacement parameters. Hydrogen atoms were added at calculated 
positions to carbon atoms with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. The CIF files for the crystal 
structures have been deposited with the CCDC and been given the deposition numbers 
1410355 (3e), 1410356 (5g), 1410357 (3g) and 1410358 (anti-4b). 
 
General Procedure for Malonate Additions to form 8a-k 
 
Sodium hydride (60% dispersion in mineral oil, 221 mg, 5.52 mmol, 2 equiv.) was suspended 
in anhydrous tetrahydrofuran (14 mL), under an atmosphere of dry nitrogen. The mixture was 
then cooled to −18 °C (ice/acetone bath). Dimethyl malonate (632 μL, 729 mg, 5.52 mmol, 2 
equiv.) was then added dropwise (causing effervescence) and the reaction mixture was then 
stirred for 15 minutes at room temperature. The mixture was again cooled to −18 °C and the 
corresponding enone 7a-k (2.76 mmol, 1 equiv.) was added dropwise as a solution in 
anhydrous tetrahydrofuran (5 mL). The reaction was stirred for approximately 4 hours at 
room temperature. Upon completion, the reaction mixture was partitioned between diethyl 
ether (20 mL) and saturated ammonium chloride (20 mL). The aqueous phase was extracted 
with diethyl ether (3 × 20 mL) and the combined organic phases were washed with water (50 
mL) and brine (50 mL). The organic phase was then dried over magnesium sulfate and 
concentrated under reduced pressure. Material was then taken through to the next step 
without further purification. A small portion of each ketodiester product was purified by 
column chromatography for spectroscopic characterization, using silica gel and a solvent 
gradient starting at petroleum ether and reaching 1:1 petroleum ether-diethyl ether. 
 
 Dimethyl 2-(3-(furan-2-yl)-3-oxo-1-phenylpropyl)malonate 8a 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, dd, J = 1.7, 0.7, 11-H), 7.30 - 7.16 (5H, m, Ar-H), 
7.15 (1H, dd, J = 3.6, 0.7, 9-H), 6.48 (1H, dd, J = 3.6, 1.7, 10-H), 4.16 (1H, ddd, J = 9.6, 8.3, 
5.8, 4-H), 3.86 (1H, d, J = 9.6, 5-H), 3.73 (3H, s, OMe), 3.51 (3H, s, OMe), 3.39 (1H, dd, J = 
16.5, 8.3, 3-H), 3.32 (1H, dd, J = 16.5, 5.8, 3-H’); 13C NMR (75 MHz, CDCl3) δ 186.4, 
168.5, 168.0, 152.4, 146.3, 146.3, 140.0, 128.4, 128.0, 127.2, 117.2, 112.2, 57.1, 52.6*, 52.4* 
(show very fine splitting, 3 Hz), 42.1, 40.5; IR (thin film) νmax 3125, 3097, 2957, 1724, 
1664, 1563, 1473, 1455, 1430, 1403, 1352, 1332, 1294, 1268, 1236, 1218, 1195, 1152, 1095, 
1071, 1044, 1018, 1002, 980, 950, 918, 881, 860, 771, 759, 699, 683, 618, 564, 531 cm
-1
; 
HRMS MNa
+
 (C18H18O6Na) calcd 353.1001, found 353.1017. 
 
 
Dimethyl 2-(1-(4-chlorophenyl)-3-(furan-2-yl)-3-oxopropyl)malonate 8b 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, dd, J = 1.7, 0.7, 11-H), 7.21 (4H, s, Ar-H), 7.15 (1H, 
dd, J = 3.6, 0.7, 9-H), 6.49 (1H, dd, J = 3.6, 1.7, 10-H), 4.14 (1H, ddd, J = 9.5, 8.1, 6.0, 4-H), 
3.82 (1H, d, J = 9.5, 5-H), 3.74 (3H, s, OMe), 3.53 (3H, s, OMe), 3.35 (1H, dd, J = 16.7, 8.1, 
3-H) , 3.29 (1H, dd, J = 16.7, 6.0, 3-H’); 13C NMR (75 MHz, CDCl3) δ 186.2, 168.3, 167.8, 
152.5, 146.4, 138.7, 133.0, 129.5, 128.6, 117.2, 112.3, 56.9, 52.7, 52.5, 41.9, 39.9; IR (thin 
film) νmax 3131, 2956, 2853, 1743, 1726, 1662, 1562, 1491, 1467, 1433, 1417, 1399, 1307, 
1274, 1251, 1199, 1157, 1113, 1090, 1069, 1039, 1022, 993, 945, 928, 910, 831 cm
-1
; HRMS 
MNa
+
 (C18H17O6NaCl) calcd 387.0611, found 387.0619. 
 
Dimethyl 2-(3-(furan-2-yl)-1-(4-methoxyphenyl)-3-oxopropyl)malonate 8c 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, dd, J = 1.7, 0.7, 11-H), 7.17 (2H, d, J = 8.7, Ar-H), 
7.15 (1H, m, 9-H), 6.77 (2H, d, J = 8.7, Ar-H’), 6.48 (1H, dd, J = 3.6, 1.7, 10-H), 4.11 (1H, 
ddd, J = 9.6, 8.2, 6.1, 4-H), 3.81 (1H, d, J = 9.6, 5-H), 3.74 (3H, s, OMe), 3.73 (3H, s, OMe), 
3.51 (3H, s, OMe), 3.40-3.38 (2H, m, 3-H,H’); 13C NMR (75 MHz, CDCl3) δ 186.6, 168.7, 
168.1, 158.5, 152.5, 146.3, 131.9, 129.1, 117.2, 113.8, 112.2, 57.4, 55.1, 52.7, 42.3, 40.0; IR 
(thin film) νmax 3126, 3098, 2956, 2838, 1727, 1665, 1612, 1583, 1515, 1474, 1431, 1421, 
1402, 1289, 1270, 1252, 1233, 1192, 1179, 1159, 1115, 1089, 1078, 1045, 1032, 998, 981, 
951, 919, 881, 827, 769, 734, 677, 598, 563, 533 cm
-1
; HRMS MNa
+
 (C19H20O7Na) calcd 
383.1107, found 383.1094. 
 
 
Dimethyl 2-(3-(furan-2-yl)-3-oxo-1-(p-tolyl)propyl)malonate 8d 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, d, J = 1.6, 11-H), 7.15 (1H, d, J = 3.6, 9-H), 7.13 
(2H, d, J = 8.0, Ar-H), 7.04 (2H, d, J = 8.0, Ar-H’), 6.48 (1H, dd, J = 3.6, 1.6, 10-H), 4.12 
(1H, ddd, J = 9.5, 8.1, 6.0, 4-H), 3.82 (1H, d, J = 9.5, 5-H), 3.73 (3H, s, OMe), 3.51 (3H, s, 
OMe), 3.21 (1H, dd, J = 16.6, 8.1, 3-H), 3.32 (1H, dd, J = 16.6, 6.0, 3-H’), 2.26 (3H, s, Ar-
Me); 
13
C NMR (75 MHz, CDCl3) δ 186.6, 168.6, 168.1, 152.5, 146.3, 136.9, 136.8, 129.2, 
127.8, 117.2, 112.2, 57.3, 52.7, 52.4, 42.2, 40.2, 21.0; IR (thin film) νmax 3126, 3097, 2948, 
1743, 1730, 1665, 1565, 1516, 1473, 1433, 1401, 1347, 1319, 1306, 1273, 1250, 1241, 1194, 
1116, 1089, 1076, 1044, 1022, 992, 974, 951, 929, 912, 882, 854, 820, 778, 770, 735, 720, 
596, 552 cm
-1
; HRMS MNa
+
 (C19H20O6Na) calcd 367.1158, found 367.1174. 
 
 
Dimethyl 2-(1-(3,4-dimethoxyphenyl)-3-(furan-2-yl)-3-oxopropyl)malonate 8e 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, dd, J = 1.7, 0.7, 11-H), 7.14 (1H, dd, J = 3.6, 0.7, 9-
H), 6.81 – 6.70 (3H, m, Ar-H), 6.48 (1H, dd, J = 3.6, 1.7, 10-H), 4.10 (1H, ddd, J = 9.3, 8.9, 
5.3, 4-H), 3.83 (1H, d, J = 9.3, 5-H), 3.82 (3H, s, OMe), 3.80 (3H, s, OMe), 3.72 (3H, s, 
OMe), 3.52 (3H, s, OMe), 3.35 (1H, dd, J = 16.4, 8.9, 3-H) , 3.26 (1H, dd, J = 16.4, 5.3, 3-
H’); 13C NMR (75 MHz, CDCl3) δ 186.6, 168.6, 168.1, 152.5, 148.5, 147.9, 146.3, 132.5, 
119.8, 117.2, 112.2, 111.4, 110.9, 57.3, 55.8, 55.7, 52.7, 52.5, 42.1, 40.3; IR (thin film) νmax 
2953, 2838, 1732, 1671, 1592, 1568, 1518, 1465, 1435, 1394, 1257, 1236, 1195, 1142, 1025, 
910, 883, 766, 728, 646, 595 cm
-1
; HRMS MNa
+
 (C20H22O8Na) calcd 413.1212, found 
413.1216. 
 
 
Dimethyl 2-(1-(4-bromophenyl)-3-(furan-2-yl)-3-oxopropyl)malonate 8f 
 
1
H NMR (300 MHz, CDCl3) δ 7.51 (1H, dd, J = 1.6, 0.7, 11-H), 7.34 (2H, d, J = 8.5, Ar-H), 
7.15 - 7.11 (3H, m, Ar-H’, 9-H), 6.46 (1H, dd, J = 3.6, 1.6, 10-H), 4.12 (1H, ddd, J = 9.3, 8.5, 
5.7, 4-H), 3.80 (1H, d, J = 9.3, 5-H), 3.70 (3H, s, OMe), 3.49 (3H, s, OMe), 3.34 (1H, dd, J = 
16.7, 8.5, 3-H) , 3.27 (1H, dd, J = 16.7, 5.7, 3-H’); 13C NMR (75 MHz, CDCl3) δ 186.0, 
168.2, 167.7, 152.2, 146.4, 139.1, 131.4, 129.8, 121.0, 117.2, 112.2, 56.7, 52.6, 52.4, 41.7, 
39.8; IR (thin film) νmax 3131, 2955, 2924, 2854, 1740, 1724, 1660, 1561, 1488, 1466, 1432, 
1411, 1332, 1306, 1253, 1217, 1200, 1155, 1084, 1065, 1021, 1011, 991, 944, 927, 909, 875, 
846, 827, 813, 793, 765, 554 cm
-1
; HRMS MNa
+
 (C18H17O6NaBr) calcd 431.0106, found 
431.0119. 
 
Dimethyl 2-(3-(furan-2-yl)-3-oxo-1-(2,4,5-trimethoxyphenyl)propyl)malonate 8g 
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (1H, dd, J = 1.7, 0.6, 11-H), 7.16 (1H, dd, J = 3.6, 0.6, 9-
H), 6.71 (1H, s, Ar-H), 6.48 (1H, dd, J = 3.6, 1.7, 10-H), 6.43 (1H, s, Ar-H’), 4.23 – 4.13 
(2H, m, 5-H,4-H), 3.83 (3H, s, OMe), 3.81 (3H, s, OMe’), 3.76 (3H, s, OMe’’), 3.73 (3H, s, 
OMe’’’), 3.54 – 3.44 (4H, m, OMe’’’’, 3-H), 3.22 (1H, dd, J = 15.9, 4.0, 3-H’); 13C NMR (75 
MHz, CDCl3) δ 187.1, 169.0, 168.4, 152.6, 151.6, 148.6, 146.2, 142.3, 118.6, 117.1, 114.3, 
112.1, 97.3, 56.4, 56.1, 55.9, 54.9, 52.5, 52.3, 40.5, 37.8; IR (thin film) νmax 2953, 2837, 
1733, 1672, 1611, 1568, 1511, 1466, 1436, 1205, 1154, 1128, 1030, 915, 883, 859, 832, 768, 
733, 702 cm
-1
 
 
Dimethyl 2-(1-(4-bromophenyl)-3-(5-methylfuran-2-yl)-3-oxopropyl)malonate 8h 
 
1
H NMR (300 MHz, CDCl3) δ 7.36 (2H, d, J = 8.5, Ar-H), 7.14 (2H, d, J = 8.5, Ar-H’), 7.07 
(1H, d, J = 3.4, 9-H), 6.10 (1H, dd, J = 3.4, 0.9, 10-H), 4.10 (1H, ddd, J = 9.6, 8.5, 5.7, 4-H), 
3.82 (1H, d, J = 9.6, 5-H), 3.73 (3H, s, OMe), 3.52 (3H, s, OMe), 3.25 (1H, dd, J = 16.4, 8.5, 
3-H), 3.23 (1H, dd, J = 16.4, 5.7, 3-H’), 2.34 (3H, s, 11-Me); 13C NMR (75 MHz, CDCl3) δ 
185.3, 168.3, 167.9, 157.9, 151.1, 139.2, 131.5, 129.9, 121.1, 119.4, 109.0, 56.8, 52.8, 52.5, 
41.5, 40.2, 14.0; IR (thin film) νmax 2953, 2923, 2852, 1730, 1660, 1514, 1488, 1433, 1241, 
1206, 1159, 1074, 1038, 992, 960, 909, 826, 795, 765, 718, 692, 556 cm
-1
; HRMS MNa
+
 
(C19H19O6NaBr) calcd 445.0263, found 445.0278. 
 
Dimethyl 2-(3-(5-methylfuran-2-yl)-3-oxo-1-phenylpropyl)malonate 8i 
 
1
H NMR (300 MHz, CDCl3) δ 7.27 – 7.23 (5H, m, Ar-H), 7.07 (1H, d, J = 3.4, 9-H), 6.09 
(1H, d, J = 3.4, 10-H), 4.14 (1H, ddd, J = 9.6, 8.3, 5.7, 4-H), 3.86 (1H, d, J = 9.6, 5-H), 3.73 
(3H, s, OMe), 3.49 (3H, s, OMe), 3.28 (1H, dd, J = 16.1, 8.3, 3-H), 3.26 (1H, dd, J = 16.1, 
5.7, 3-H’), 2.35 (3H, s, 11-Me); 13C NMR (75 MHz, CDCl3) δ 185.7, 168.6, 168.1, 157.7, 
151.3, 140.1, 128.4, 128.1, 127.2, 119.3, 108.9, 57.2, 52.7, 52.4, 41.8, 40.9, 14.0; IR (thin 
film) νmax 2954, 2922, 1746, 1727, 1659, 1516, 1456, 1433, 1417, 1293, 1252, 1205, 1149, 
1074, 1040, 1027, 977, 956, 925, 904, 788, 764, 702, 564, 530 cm
-1
; HRMS MNa
+
 
(C19H20O6Na) calcd 367.1158, found 367.1140. 
 Dimethyl 2-(3-(5-methylfuran-2-yl)-3-oxo-1-(p-tolyl)propyl)malonate 8j 
 
1
H NMR (300 MHz, CDCl3) δ 7.13 (2H, d, J = 8.1, Ar-H), 7.08 (1H, d, J = 3.4, 9-H), 7.04 
(2H, d, J = 8.1, Ar-H), 6.09 (1H, dd, J = 3.4, 0.8, 10-H), 4.09 (1H, ddd, J = 9.5, 7.9, 6.0, 4-
H), 3.83 (1H, d, J = 9.5, 5-H), 3.73 (3H, s, OMe), 3.51 (3H, s, OMe), 3.26-3.10 (2H, m, 3-
H,H’), 2.34 (3H, s, 11-Me), 2.25 (3H, s, Ar-Me); 13C NMR (75 MHz, CDCl3) δ 185.8, 168.7, 
168.1, 157.7, 151.3, 137.0, 136.7, 129.1, 127.9, 119.3, 108.9, 57.3, 52.6, 52.4, 41.9, 40.5, 
21.0, 14.0; IR (thin film) νmax 2953, 2922, 2852, 1749, 1729, 1660, 1515, 1432, 1360, 1379, 
1301, 1239, 1221, 1196, 1144, 1115, 1081, 1041, 983, 959, 906, 816, 794, 722, 560, 533 cm
-
1
; HRMS MNa
+
 (C20H22O6Na) calcd 381.1314, found 381.1311. 
 
Dimethyl 2-(1-(4-chlorophenyl)-3-(5-methylfuran-2-yl)-3-oxopropyl)malonate 8k 
1
H NMR (300 MHz, CDCl3) δ 7.13 (4H, s, Ar-H), 7.06 (1H, d, J = 3.5, 9-H), 6.08 (1H, d, J = 
3.5, 10-H), 4.07 (1H, ddd, J = 9.7, 8.6, 5.6, 4-H), 3.79 (1H, d, J = 9.7, 5-H), 3.71 (3H, s, 
OMe), 3.49 (3H, s, OMe), 3.22 (1H, dd, J = 16.3, 8.6, 3-H), 3.20 (1H, dd, J = 16.3, 5.6, 3-
H’), 2.30 (3H, s, 11-Me); 13C NMR (75 MHz, CDCl3) δ 185.5, 168.4, 167.9, 158.0, 151.0, 
138.5, 132.9, 129.4, 128.5, 119.6, 109.0, 57.0, 52.7, 52.5, 41.5, 40.1, 13.9; IR (thin film) νmax 
2954, 1728, 1660, 1515, 1491, 1435, 1272, 1239, 1221, 1164, 1082, 1039, 1015, 960, 907, 
828, 795, 728, 648, 559 cm
-1
 
 
General Procedure for Krapcho Decarboxylations of ketodiesters 8a-k to form 
ketoesters 9a-k 
A portion of crude keto-diester 8a-k (2.00 mmol, 1 equiv.) was dissolved in a 5:1 mixture of 
dimethyl sulfoxide and water (30 mL). To this was added lithium chloride (3.39 g, 80 mmol, 
40 equiv.) and the mixture was heated at 110 °C for 36 hours. Upon completion the reaction 
mixture was partitioned between diethyl ether (50 mL) and water (50 mL). The aqueous 
phase was extracted with diethyl ether (3 × 30 mL). The combined organic phases were then 
washed with water (2 × 100 mL) and brine (100 mL) and dried over magnesium sulfate. The 
solution was then concentrated under reduced pressure and the crude product purified by 
column chromatography using silica gel and a solvent gradient from hexane to 1:1 
hexane:diethyl ether, affording the product 9a-k.  
 
Methyl 5-(furan-2-yl)-5-oxo-3-phenylpentanoate 9a  
 
245 mg from 396 mg 7a (45%, 2 steps), m.p. 85.2-85.6 C; 1H NMR (300 MHz, CDCl3) δ 
7.52 (1H, m, 11-H), 7.28 – 7.14 (5H, m, Ar-H), 7.13 (1H, d, J = 3.6, 9-H), 6.47 (1H, m, 10-
H), 3.83 (1H, dddd, J = 7.3, 7.3, 7.3, 7.3, 4-H), 3.55 (3H, s, OMe), 3.19 (2H, d, J = 7.3, 3-H, 
3-H’), 2.78 (1H, dd, J = 15.5, 7.3, 5-H), 2.67 (1H, dd, J = 15.5, 7.3, 5-H’); 13C NMR (75 
MHz, CDCl3) δ 187.2, 172.1, 152.6, 146.3, 142.9, 128.5, 127.2, 126.8, 117.1, 112.2, 51.5, 
44.3, 40.4, 37.4; IR (thin film) νmax 3128, 3100, 2950, 1726, 1660, 1565, 1466, 1430, 1396, 
1354, 1288, 1245, 1219, 1197, 1064, 1086, 1064, 1043, 1007, 985, 952, 919, 882 cm
-1
; 
HRMS MNa
+
 (C16H16O4Na) calcd 295.0946, found 295.0945. 
 
 
Methyl 3-(4-chlorophenyl)-5-(furan-2-yl)-5-oxopentanoate 9b 
 
64 mg from 442 mg 7b (11%, 2 steps), m.p. 83.3-84.2 C; 1H NMR (300 MHz, CDCl3) δ 
7.55 (1H, m, 11-H), 7.25 (2H, d, J = 8.2, Ar-H), 7.19 (2H, d, J = 8.2, Ar-H’), 7.17 (1H, dd, J 
= 3.6, 0.4, 9-H), 6.51 (1H, dd, J = 3.6, 1.7, 10-H), 3.78 (1H, m, 4-H), 3.58 (3H, s, OMe), 3.18 
(2H, d, J = 7.2, 3-H, 3-H’), 2.78 (1H, dd, J = 15.6, 6.8, 5-H), 2.66 (1H, dd, J = 15.6, 8.2, 5-
H’); 13C NMR (75 MHz, CDCl3) δ 186.9, 171.9, 152.6, 146.4, 141.4, 132.5, 128.7 (2xC) , 
117.3, 112.3, 51.7, 44.1, 40.3, 36.8; IR (thin film) νmax 3124, 3098, 2952, 1721, 1661, 1563, 
1494, 1473, 1430, 1398, 1362, 1327, 1306, 1290, 1267, 1216, 1195, 1155, 1106, 1089, 1066, 
1042, 1014, 1000, 986, 950, 920, 906, 881, 873, 827, 770, 730, 709, 597, 536, 519 cm
-1
; 
HRMS MNa
+
 (C16H15O4NaCl) calcd 329.0557, found 329.0566. 
 
Methyl 5-(furan-2-yl)-3-(4-methoxyphenyl)-5-oxopentanoate 9c 
 
108 mg from 479 mg 7c (17%, 2 steps), viscous oil; 
1
H NMR (300 MHz, CDCl3) δ 7.54 (1H, 
m, 11-H), 7.19 – 7.13 (3H, m, Ar-H, 9-H), 6.80 (2H, d, J = 8.57, Ar-H’), 6.49 (1H, dd, J = 
3.5, 1.2, 10-H), 3.83 (1H, m, 4-H), 3.75 (3H, s, OMe), 3.57 (3H, s, OMe), 3.16 (2H, d, J = 
7.2, 3-H, 3-H’), 2.76 (1H, dd, J = 15.4, 6.9, 5-H), 2.64 (1H, dd, J = 15.4, 8.1, 5-H’); 13C 
NMR (75 MHz, CDCl3) δ 186.9, 171.8, 157.9, 152.2, 146.1, 146.1, 134.6, 127.9, 116.9, 
113.5, 111.9, 54.7, 54.6, 51.1, 51.0, 44.1, 40.2, 36.4; IR (thin film) νmax 2952, 2837, 1731, 
1669, 1611, 1583, 1567, 1512, 1466, 1435, 1394, 1364, 1300, 1278, 1245, 1177, 1152, 1112, 
1085, 1029, 915, 882, 829, 763, 729, 594, 557 cm
-1
; HRMS MNa
+
 (C17H18O5Na) calcd 
325.1052, found 325.1059. 
 
Methyl 5-(furan-2-yl)-5-oxo-3-(p-tolyl)pentanoate 9d 
 
201 mg from 425 mg 7d (35 %, 2 steps), viscous oil; 
1
H NMR (300 MHz, CDCl3) δ 7.54 
(1H, dd, J = 1.7, 0.7, 11-H), 7.17 – 7.06 (5H, m, Ar-H, 9-H), 6.50 (1H, dd, J = 3.6, 1.7, 10-
H), 3.83 (1H, dddd, J = 7.6, 7.3, 7.3, 7.3, 4-H), 3.58 (3H, s, OMe), 3.18 (2H, d, J = 7.3, 3-H, 
3-H’), 2.78 (1H, dd, J = 15.5, 7.3, 5-H), 2.66 (1H, dd, J = 15.5, 7.6, 5-H’), 2.28 (3H, s, Ar-
Me); 
13
C NMR (75 MHz, CDCl3) δ 187.3, 172.2, 152.6, 146.3, 139.8, 136.3, 129.2, 127.0, 
117.2, 112.2, 51.5, 44.4, 40.5, 37.0, 21.0; IR (thin film) νmax 3131, 3022, 2951, 2921, 1732, 
1670, 1592, 1568, 1515, 1467, 1449, 1435, 1394, 1362, 1314, 1276, 1211, 1193, 1154, 1085, 
1019, 990, 914, 883, 816, 762, 722, 695 cm
-1 
 
 
Methyl 3-(3,4-dimethoxyphenyl)-5-(furan-2-yl)-5-oxopentanoate 9e 
 
117 mg from 480 mg 7e (19%, 2 steps), m.p. 94.4-95.6 C; 1H NMR (300 MHz, CDCl3) δ 
7.55 (1H, dd, J = 1.7, 0.6, 11-H), 7.13 (1H, dd, J = 3.6, 0.6, 9-H), 6.75 (3H, s (br), Ar-H), 
6.48 (1H, dd, J = 3.6, 1.7, 10-H), 3.83 (3H, s, OMe), 3.80 (3H, s, OMe), 3.78 (1H, m, 4-H), 
3.56 (3H, s, OMe), 3.16 (2H, d, J = 7.4, 3-H, 3-H’), 2.75 (1H, dd, J = 15.4, 7.0, 5-H), 2.65 
(1H, dd, J = 15.4, 8.0, 5-H’); 13C NMR (75 MHz, CDCl3) δ 187.3, 172.1, 152.6, 148.7, 147.6, 
146.3, 135.5, 118.9, 117.1, 112.2, 111.1, 110.7, 55.7, 55.7, 51.5, 44.4, 40.6, 37.1; IR (thin 
film) νmax 3130, 3100, 3008, 2957, 2836, 1735, 1658, 1589, 1562, 1519, 1465, 1438, 1425, 
1397, 1329, 1293, 1281, 1254, 1230, 1187, 1160, 1142, 1087, 1039, 1019, 999, 974, 919, 
895, 881, 859, 847, 805, 776, 763, 734, 642, 661, 596, 566, 538, 520 cm
-1
; HRMS MNa
+
 
(C18H20O6Na) calcd 355.1158, found 355.1166. 
 
Methyl 3-(4-bromophenyl)-5-(furan-2-yl)-5-oxopentanoate 9f 
 
190 mg from 571 mg 7f (26 %, 2 steps), m.p. 83.9-95 C; 1H NMR (300 MHz, CDCl3) δ 7.55 
(1H, dd, J = 1.6, 0.7, 11-H), 7.40 (2H, d, J = 8.5, Ar-H), 7.17 – 7.12 (3H, m, Ar-H’, 9-H), 
6.51 (1H, dd, J = 3.6, 1.6, 10-H), 3.82 (1H, dddd, J = 7.9, 7.2, 7.2, 7.0, 4-H), 3.59 (3H, s, 
OMe), 3.18 (2H, d, J = 7.2, 3-H, 3-H’), 2.78 (1H, dd, J = 15.7, 7.0, 5-H), 2.65 (1H, dd, J = 
15.7, 7.9, 5-H’); 13C NMR (75 MHz, CDCl3) δ 186.9, 171.9, 152.5, 146.4, 141.9, 131.6, 
129.1, 120.6, 117.3, 112.3, 51.7, 44.0, 40.2, 36.8; IR (thin film) νmax 3124, 3097, 2951, 1722, 
1662, 1563, 1488, 1472, 1430, 1398, 1361, 1326, 1306, 1290, 1267, 1214, 1193, 1160, 1105, 
1077, 1065, 1041, 1010, 1000, 986, 950, 920, 906, 881, 873, 824, 769, 724, 703, 610, 535, 
518 cm
-1
; HRMS MNa
+
 (C16H15O4NaBr) calcd 373.0051, found 373.0069. 
 
Methyl 5-(furan-2-yl)-5-oxo-3-(2,4,5-trimethoxyphenyl)pentanoate 9g 
 
347 mg from 499 mg 7g (55 %, 2 steps), gum; 
1
H NMR (300 MHz, CDCl3) δ 7.55 (1H, dd, J 
= 1.6, 0.6, 11-H), 7.16 (1H, dd, J = 3.6, 0.6, 9-H), 6.73 (1H, s, Ar-H), 6.49 (1H, dd, J = 3.6, 
1.6, 10-H), 6.47 (1H, s, Ar-H’), 4.00 (1H, m , 4-H), 3.84 (3H, s, OMe), 3.80 (3H, s, OMe), 
3.79 (3H, s, OMe), 3.58 (3H, s, OMe), 3.26 (1H, dd, J = 14.7, 6.0, 3-H), 3.18 (1H, dd, J = 
14.7, 6.2, 3-H’), 2.83 (1H, dd, J = 13.2, 4.9, 5-H), 2.76 (1H, dd, J = 13.2, 5.2, 5-H’); 13C 
NMR (75 MHz, CDCl3) δ 188.0, 172.7, 152.7, 151.3, 148.2, 146.3, 142.6, 121.8, 117.2, 
112.8, 112.1, 97.6, 56.5, 56.2, 56.0, 51.5, 42.8, 38.6, 33.4; IR (thin film) νmax 2950, 2835, 
1733, 1671, 1611, 1568, 1511, 1467, 1438, 1397, 1314, 1276, 1206, 1163, 1122, 1031, 916, 
883, 830, 767 cm
-1
 
 
Methyl 3-(4-bromophenyl)-5-(5-methylfuran-2-yl)-5-oxopentanoate 9h 
 
262 mg from 585 mg 7h (36 %, 2 steps), m.p. 77.6-79.0 C; 1H NMR (300 MHz, CDCl3) δ 
7.39 (2H, d, J = 8.4, Ar-H), 7.14 (2H, d, J = 8.4, Ar-H’), 7.06 (1H, d, J = 3.4, 9-H), 6.12 (1H, 
dd, J = 3.4, 0.8, 10-H), 3.76 (1H, m, 4-H), 3.58 (3H, s, OMe), 3.11 (2H, d, J = 7.3, 3-H, 3-
H’), 2.78 (1H, dd, J = 15.7, 8.3, 5-H), 2.65 (1H, dd, J = 15.7, 8.3, 5-H’), 2.36 (3H, s, 11-Me); 
13
C NMR (75 MHz, CDCl3) δ 186.1, 171.9, 158.0, 151.3, 142.0, 131.6, 129.1, 120.6, 119.4, 
109.1, 51.7, 43.8, 40.2, 37.1, 14.1; IR (thin film) νmax 2952, 2916, 1735, 1654, 1590, 1516, 
1489, 1448, 1437, 1421, 1407, 1386, 1366, 1306, 1291, 1220, 1209, 1195, 1178, 1165, 1104, 
1087, 1070, 1036, 1025, 1010, 987, 959, 950, 933, 910, 873, 823, 792, 725, 706, 670, 526 
cm
-1
; HRMS MNa
+
 (C17H17O4NaBr) calcd 387.0208, found 387.0225. 
 
Methyl 5-(5-methylfuran-2-yl)-5-oxo-3-phenylpentanoate 9i 
 
154 mg from 374 mg 7i (31%, 2 steps), m.p. 99.3-100.6C; 1H NMR (300 MHz, CDCl3) δ 
7.36 – 7.12 (5H, m, Ar-H), 7.06 (1H, d, J = 3.5, 9-H), 6.11 (1H, dd, J = 3.5, 0.8, 10-H), 3.83 
(1H, m, 4-H), 3.57 (3H, s, OMe), 3.13 (2H, d, J = 7.2, 3-H, 3-H’), 2.80 (1H, dd, J = 15.5, 6.8, 
5-H), 2.69 (1H, dd, J = 15.5, 8.1, 5-H’), 2.36 (3H, s, 11-Me); 13C NMR (75 MHz, CDCl3) δ 
186.5, 172.2, 157.8, 151.5, 143.1, 128.6, 127.3, 126.8, 119.2, 109.0, 51.5, 44.1, 40.4, 37.8, 
14.0; IR (thin film) νmax 2952, 1730, 1659, 1515, 1495, 1436, 1456, 1372, 1360, 1284, 1248, 
1226, 1211, 1161, 1090, 1074, 1034, 989, 978, 954, 931, 882, 796, 783, 761, 699, 559 cm
-1
 
 
 
 
 
Methyl 5-(5-methylfuran-2-yl)-5-oxo-3-(p-tolyl)pentanoate 9j 
 
177 mg from 434 mg 7j (31 %, 2 steps), m.p. 79.3-80.2 C; 1H NMR (300 MHz, CDCl3) δ 
7.16 – 7.06 (5H, m, Ar-H, 9-H), 6.10 (1H, dd, J = 3.5, 0.8, 10-H), 3.79 (1H, dddd, J = 7.6, 
7.3, 7.3, 7.0, 4-H), 3.56 (3H, s, OMe), 3.10 (2H, d, J = 7.3, 3-H, 3-H’), 2.77 (1H, dd, J = 
15.5, 7.0, 5-H), 2.65 (1H, dd, J = 15.5, 7.6, 5-H’), 2.34 (3H, s, Me), 2.27 (3H, s, Me); 13C 
NMR (75 MHz, CDCl3) δ 186.5, 172.2, 157.7, 151.3, 138.9, 136.1, 129.1, 127.0, 119.2, 
108.8, 51.4, 44.1, 40.3, 37.2, 20.9, 13.9; IR (thin film) νmax 2951, 2920, 1729, 1659, 1515, 
1448, 1435, 1422, 1385, 1368, 1334, 1312, 1296, 1270, 1223, 1211, 1180, 1162, 1113, 1085, 
1072, 1037, 1026, 991, 958, 873, 816, 795, 755, 722, 666, 528 cm
-1
; HRMS MNa
+
 
(C18H20O4Na) calcd 323.1259, found 323.1248. 
 
Methyl 3-(4-chlorophenyl)-5-(5-methylfuran-2-yl)-5-oxopentanoate 9k 
 
177 mg from 466 mg 7k (29 %, 2 steps), m.p. 65.7-66.5 C; 1H NMR (300 MHz, CDCl3) δ 
7.23 – 7.14 (4H, m, Ar-H), 7.04 (1H, d, J = 3.5, 9-H), 6.09 (1H, dd, J = 3.5, 0.8, 10-H), 3.79 
(1H, dddd, J = 7.6, 7.2, 7.2, 7.0, 4-H), 3.54 (3H, s, OMe), 3.09 (2H, d, J = 7.2, 3-H, 3-H’), 
2.76 (1H, dd, J = 15.6, 7.0, 5-H), 2.63 (1H, dd, J = 15.6, 7.9, 5-H’), 2.32 (3H, s, 11-Me); 13C 
NMR (75 MHz, CDCl3) δ 186.0, 171.8, 157.8, 151.2, 141.4, 132.3, 128.6, 128.5, 119.3, 
108.9, 51.5, 43.7, 40.1, 36.9, 13.9; IR (thin film) νmax 2998, 2953, 2920, 1735, 1654, 1591, 
1514, 1492, 1448, 1438, 1423, 1411, 1385, 1369, 1329, 1306, 1291, 1271, 1220, 1209, 1196, 
1178, 1164, 1105, 1088, 1071, 1036, 1026, 1014, 987, 959, 912, 887, 873, 825, 791, 729, 
711, 672, 537, 526 cm
-1
; HRMS MNa
+
 (C17H17O4NaCl) calcd 343.0713, found 343.0706. 
 
General Procedure for the reduction of ketoesters 9a-k to form diols 1a-k 
 
Solid lithium aluminium hydride (304 mg, 8.00 mmol, 10 equiv.) was suspended in 
anhydrous tetrahydrofuran (4 mL) under dry nitrogen. The reaction mixture was cooled to 
−15 °C. Keto-ester 9a-k (0.80 mmol, 1 equiv.) was added dropwise in anhydrous 
tetrahydrofuran (5 mL) at this temperature. The reaction mixture was then stirred at room 
temperature for a further 15 minutes after which TLC analysis indicated that reaction was 
complete. The reaction was quenched by adding diethyl ether (10 mL) followed by the slow 
dropwise addition of a 4:1 mixture of diethyl ether and acetone (15 mL). The reaction 
mixture was then diluted in ethyl acetate (40 mL) and washed with water (100 mL) and 2.0 M 
aqueous sodium hydroxide (150 mL). The combined aqueous phase was extracted with ethyl 
acetate (5 × 50 mL). The combined organic phases were then washed with water (2 × 100 
mL) and brine (100 mL) before being dried over magnesium sulfate. The organic phase was 
then concentrated under reduced pressure to afford the product 1a-k as a colorless oil which 
was used without any further purification (except in the case of 1b, whose diastereomers 
were able to be partly separated by careful column chromatography, using a solvent gradient 
from petroleum ether to diethyl ether). In general, 
1
H NMR data for each diastereomer in the 
mixtures are listed sequentially, although signals from each diastereomer were often 
significantly overlapped. For 1b, the 
1
H, 
13
C, IR and MS data for each diastereomer is listed 
separately.  
 
1-(Furan-2-yl)-3-phenylpentane-1,5-diol 1a  
 
195 mg from 218 mg 9a, 99 %, d.r. = 1:0.7; 
1
H NMR (300 MHz, CD3CN) δ major  
diastereomer: 7.44 (1H, dd, J = 1.8, 0.8, 11-H), 7.36 – 7.23 (5H, m, Ar-H), 6.37 (1H, dd, J = 
3.2, 1.8, 10-H), 6.20 (1H, d, J = 3.2, 9-H), 4.33 (1H, dd, J = 7.3, 7.3, 2-H), 3.45 – 3.15 (3H, 
m, 6-H,H’,OH), 2.69 – 2.54 (2H, m, 4-H,OH), 2.24 – 1.64 (4H, m, 3-H,H’, 5-H,H); minor  
diastereomer: 7.36 (1H, dd, J = 1.8, 0.8, 11-H), 7.36 – 7.23 (5H, m, Ar-H), 6.31 (1H, dd, J = 
3.2, 1.8, 10-H), 6.14 (1H, d, J = 3.2, 9-H), 4.18 (1H, dd, J = 10.0, 3.2, 2-H), 3.45 – 3.15 (3H, 
m, 6-H,H’,OH), 3.03 (H, m, b-4-H), 2.69 – 2.54 (1H, m, OH), 2.24 – 1.64 (4H, m, 3-H’,H’, 
5-H,H’); 13C NMR (75 MHz, CD3CN) δ 159.0, 157.9, 145.9, 145.5, 142.8, 142.5, 129.3, 
128.8, 128.5, 127.1, 111.0, 110.9, 107.0, 105.9, 65.7, 65.2, 60.4, 60.2, 43.2, 43.1, 40.6, 39.9, 
39.3, 39.0; IR (thin film) νmax 3318 (br), 2921, 2850, 1494, 1453, 1260, 1145, 1043, 1009, 
913, 884, 808, 762, 740, 701, 634, 598, 533 cm
-1
; HRMS MNa
+
(C15H18O3Na) calcd 
269.1154, found 269.1145. 
 
3-(4-Chlorophenyl)-1-(furan-2-yl)pentane-1,5-diol 1b 
 
55 mg from 61 mg 9b, 99 %, d.r. = 1:0.75, separable by column chromatography; 
major  diastereomer:
 1
H NMR (300 MHz, CDCl3) δ 7.38 (1H, dd, J = 1.8, 0.8, 11-H), 7.27 
(2H, d, J = 8.4, Ar-H), 7.08 (2H, d, J = 8.4, Ar-H’), 6.33 (1H, dd, J = 3.2, 1.8, 10-H), 6.17 
(1H, d, J = 3.2, 9-H), 4.49 (1H, dd, J = 6.2, 6.2, 2-H), 3 52 (1H, m, 6-H), 3.39 (1H, m, 6-H’), 
2.71 (1H, m, 4-H), 2.30 – 1.70 ([4H, m, 3-H,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 
155.7, 142.7, 142.2, 132.1, 128.9, 128.7, 110.2, 106.7, 65.6, 60.5, 42.1, 38.8, 38.0; IR (thin 
film) νmax 3328 (br), 2938, 2885, 1489, 1467, 1450, 1412, 1146, 1091, 1042, 1012, 940, 908, 
883, 824, 730, 597, 566 cm
-1
 
minor  diastereomer: 
1
H NMR (300 MHz, CDCl3) δ 7.32 (1H, dd, J = 1.8, 0.8, 11-H), 7.28 
(2H, d, J = 8.5, Ar-H), 7.17 (2H, d, J = 8.5, Ar-H’), 6.29 (1H, dd, J = 3.2, 1.8, 10-H), 6.14 
(1H, ddd, J = 3.2, 0.8, 0.7, 9-H), 4.33 (1H, d, J = 10.4, 2-H), 3.65 – 3.40 (2H, m, 6-H,H’), 
3.14 (1H, m, 4-H), 2.22 (1H, ddd, J = 14.2, 10.4, 4.2, 3-H), 2.05 – 1.80 (3H, m, 3-H’, 5-
H,H’); 13C NMR (75 MHz, CDCl3) δ 156.7, 155.7, 142.7, 142.3, 141.93, 141.87, 132.1, 
129.2, 128.9, 128.77, 128.75, 110.2, 110.1, 106.8, 105.6, 65.7, 65.0, 60.6, 60.5, 42.1, 41.8, 
39.6, 38.9, 38.0, 37.7; IR (thin film) νmax 3314 (br), 2932, 1489, 1434, 1412, 1320, 1146, 
1090, 1043, 1012, 884, 824, 737, 634, 598, 534 cm
-1   
 
 
 
1-(Furan-2-yl)-3-(4-methoxyphenyl)pentane-1,5-diol 1c 
 
188 mg from 215 mg 9c, 96 %, d.r. = 1:0.75; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.39 (1H, d, J = 1.7, 11-H), 7.07 (2H, d, J = 8.3, Ar-H), 6.87 – 6.84 (2H, m, 
Ar-H’), 6.33 (1H, dd, J = 2.7, 1.7, 10-H), 6.19 (1H, d, J = 2.7, a-9-H), 4.51 (1H, dd, J = 11.2, 
5.9, a-2-H), 3.80 (3H, s(br), Ar-OMe), 3.62 – 3.38 (2H, m, 6-H,H’), 2.68 – 2.59 (1H, m, a-4-
H), 2.29 – 1.79 (4H, m, a-3-H,H’, 5-H,H’); minor  diastereomer: 7.32 (1H, m, 11-H), 7.15 
(2H, d, J = 8.5, Ar-H), 6.87 – 6.84 (2H, m, Ar-H’), 6.29 (1H, dd, J = 3.0, 1.6, 10-H), 6.15 
(1H, d, J = 3.0, 9-H), 4.37 (1H, dd, J = 8.8, 3.6, 2-H), 3.80 (3H, s(br), Ar-OMe), 3.62 – 3.38 
(2H, m, 6-H,H’), 3.13 – 3.02 (1H, m, 4-H), 2.29 – 1.79 (4H, m, 3-H’,H’, 5-H,H’); 13C NMR 
(75 MHz, CDCl3) δ 158.3, 157.1, 156.0, 142.2, 141.8, 136.0, 135.6, 128.7, 128.5, 114.12, 
114.10, 110.1, 106.7, 105.4, 66.1, 65.3, 61.1, 60.9, 55.3, 42.6, 42.3, 40.0, 39.4, 38.2, 37.7; IR 
(thin film) νmax 3347(br), 2933, 1609, 1510, 1441, 1365, 1301, 1243, 1177, 1146, 1029, 1008, 
830, 736, 598, 574 cm
-1
; HRMS MNa
+
 (C16H20O4Na) calcd 299.1259, found 299.1273.  
 
 
 
1-(furan-2-yl)-3-(p-tolyl)pentane-1,5-diol 1d 
 
62 mg from 101 mg 9d, 68 %, d.r. = 1:0.74; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.38 (1H, dd, J = 1.8, 0.8, 11-H), 7.13 – 7.02 (4H, m, Ar-H), 6.33 (1H, dd, J = 
3.2, 1.8, 10-H), 6.18 (1H, d, J = 3.2, 9-H), 4.52 (1H, dd, J = 7.2, 7.2, 2-H), 3.61 – 3.38 (2H, 
m, 6-H,H), 2.66 (1H, m, 4-H), 2.33 (3H, s(br), Ar-Me), 2.28 – 1.72 (4H, m, 3-H,H’, 5-H,H’); 
minor  diastereomer: 7.32 (1H, dd, J = 1.8, 0.8, 11-H), 7.13 – 7.02 (4H, m, Ar-H), 6.28 (1H, 
dd, J = 3.2, 1.8, 10-H), 6.14 (1H, d, J = 3.2, 9-H), 4.36 (1H, ddd, J = 10.2, 2.8, 2-H), 3.61 – 
3.38 (2H, m, 6-H,H’), 3.08 (1H, m, 4-H), 2.33 (3H, s(br), Ar-Me), 2.28 – 1.72 (4H, m, 3-
H’,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 157.0, 155.9, 142.2, 141.8, 140.9, 140.6, 
136.11, 136.08, 129.4, 127.6, 127.4, 110.11, 110.08, 106.7, 105.4, 66.0, 65.2, 61.1, 60.9, 
42.4, 42.0, 39.8, 39.2, 38.5, 38.0, 21.0; IR (thin film) νmax 3317 (br), 2924, 1512, 1145, 1042, 
1008, 884, 814, 735, 598, 572, 491 cm
-1
; HRMS MNa
+
 (C16H20O3Na) calcd 283.1310, found 
283.1320. 
 
3-(3,4-dimethoxyphenyl)-1-(furan-2-yl)pentane-1,5-diol 1e 
 
92 mg from 105 mg 9e, 95 %, d.r. = 1:0.8; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.44 (1H, dd, J = 1.8, 0.8, 11-H), 6.84 (1H, d, J = 8.2, Ar-H), 6.70 (1H, d, J = 
2.0, Ar-H’), 6.65 (1H, dd, J = 8.2, 2.0, Ar-H’’), 6.37 (1H, dd, J = 3.2, 1.8, 10-H), 6.20 (1H, d, 
J = 3.2, 9-H), 4.33 (1H, ddd, J = 8.3, 6.0, 6.0, 2-H), 3.77 (6H, s, OMe,OMe’), 3.41 – 3.16 
(3H, m, 6-H,H’,OH), 2.60 – 2.44 (2H, 4-H,OH), 2.20 – 1.60 (4H, m, 3-H,H’, 5-H,H’); minor  
diastereomer: 7.36 (1H, dd, J = 1.8, 0.8, 11-H), 6.86 (1H, d, J = 8.1, Ar-H), 6.79 (1H, d, J = 
1.9, Ar-H’), 6.75 (1H, dd, J = 8.1, 1.9, Ar-H’’), 6.31 (1H, dd, J = 3.2, 1.8, 10-H), 6.14 (1H, d, 
J = 3.2, 9-H), 4.20 (1H, m, 2-H), 3.774 (3H, s, OMe), 3.767 (3H, s, OMe’), 3.41 – 3.16 (3H, 
m, 6-H,H’,OH), 2.95 (1H, m, 4-H), 2.60 – 2.44 (1H, OH), 2.20 – 1.60 (4H, m, 3-H’,H’, 5-
H,H’); 13C NMR (75 MHz, CDCl3) δ 159.1, 158.1, 150.0, 148.4, 142.8, 142.5, 138.4, 138.0, 
120.7, 120.4, 112.4, 112.2, 112.0, 111.0, 107.1, 105.9, 65.8, 65.2, 60.5, 60.4, 56.1, 43.4, 43.3, 
40.6, 40.0, 39.0, 38.7; IR (thin film) νmax 3344(br), 2935, 2835, 1591, 1513, 1463, 1420, 
1256, 1232, 1139, 1024, 912, 884, 808, 763, 727, 649, 599 cm
-1
; HRMS MNa
+
(C17H22O5Na) 
calcd 329.1365, found 329.1358. 
 
3-(4-bromophenyl)-1-(furan-2-yl)pentane-1,5-diol 1f 
 
147 mg from 160 mg 9f, 99 %, d.r. = 1:0.76; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.46 – 7.40 (2H, m, Ar-H), 7.39 (1H, dd, J = 1.8, 0.8, 11-H), 7.03 (2H, d, J = 
8.4, Ar-H’), 6.33 (1H, dd, J = 3.2, 1.8, 10-H), 6.18 (1H, d, J = 3.2, 9-H), 4.49 (1H, dd, J = 
6.7, 8.0, 2-H), 3.62 (2H, m, 6-H,H), 2.69 (1H, m, 4-H), 2.30 – 1.70 (4H, m, 3-H,H’, 5-H,H’); 
minor  diastereomer: 7.46 – 7.40 (2H, m, Ar-H), 7.32 (1H, dd, J = 1.8, 0.8, 11-H), 7.12 (2H, 
d, J = 8.4, Ar-H’), 6.29 (1H, dd, J = 3.2, 1.8, 10-H), 6.14 (1H, d, J = 3.2, 9-H), 4.33 (1H, dd, 
J = 10.4, 3.2, 2-H), 3.62 (2H, m, 6-H,H’), 3.13 (1H, m, 4-H), 2.30 – 1.70 (4H, m, 3-H’,H’, 5-
H,H’); 13C NMR (75 MHz, CDCl3) δ 156.7, 155.7, 143.2, 142.8, 142.3, 141.9, 131.74, 
131.71, 129.6, 129.3, 120.2, 110.2, 110.1, 106.8, 105.6, 65.7, 65.1, 60.7, 60.5, 42.1, 41.9, 
39.6, 38.9, 38.2, 37.9; IR (thin film) νmax 3312(br), 2929, 1486, 1431, 1230, 1146, 1069, 
1042, 1008, 883, 818, 737, 598, 565, 494 cm
-1
; HRMS MNa
+
(C15H17O3NaBr) calcd 
347.0259, found 347.0245. 
 
 
 
1-(furan-2-yl)-3-(2,4,5-trimethoxyphenyl)pentane-1,5-diol 1g 
 
234 mg from 261 mg 9g, 97 %, d.r. = 1:0.65; 
1
H NMR (300 MHz, CD3CN) δ major  
diastereomer: 7.42 (1H, dd, J = 1.8, 0.8, 11-H), 6.72 (1H, s, Ar-H), 6.60 (1H, s, Ar-H’), 6.35 
(1H, dd, J = 3.2, 1.8, 10-H), 6.18 (1H, d, J = 3.2, 9-H), 4.37 (1H, m, 2-H), 3.80 ([3H, s, Ar-
OMe), 3.73 (3H, s, Ar-OMe’), 3.69 (3H, s, Ar-OMe’’), 3.40 – 3.15 (2H, m, 6-H,H), 3.02 (1H, 
dddd, J = 9.3, 9.3, 5.9, 5.9, 4-H), 2.19 – 1.98 (2H, m, 3-H,H’), 1.90 – 1.64 (2H, m, 5-H,H’); 
minor  diastereomer: 7.36 (1H, dd, J = 1.8, 0.8, 11-H), 6.73 (1H, s, Ar-H), 6.64 (1H, s, Ar-
H’), 6.30 (1H, dd, J = 3.2, 1.8, 10-H), 6.15 (1H, d, J = 3.2, 9-H), 4.24 (1H, m, 2-H), 3.80 (3H, 
s, Ar-OMe), 3.78 (3H, s, Ar-OMe’), 3.72 (3H, s, Ar-OMe’’), 3.40 – 3.15 (3H, m, 4-H,6-
H,H’), 2.19 – 1.98 (2H, m, 3-H,H’), 1.90 – 1.64 (2H, m, 5-H,H’); 13C NMR (75 MHz, 
CD3CN) δ 158.9, 158.4, 152.9, 152.6, 149.0, 148.9, 144.5, 144.2, 142.6, 142.5, 124.9, 124.5, 
113.5, 111.0, 110.9, 106.8, 106.0, 99.8, 99.4, 65.9, 65.8, 60.8, 60.7, 57.5, 57.1, 57.0, 56.5, 
42.3, 42.2, 39.6, 39.1, 31.9; IR (thin film) νmax 3391 (br), 2929, 2853, 1509, 1464, 1440, 
1398, 1315, 1273, 1203, 1180, 1147, 1121, 1031, 910, 860, 883, 813 cm
-1
; HRMS 
MNa
+
(C18H24O6Na) calcd 359.1471, found 359.1466. 
 
3-(4-bromophenyl)-1-(5-methylfuran-2-yl)pentane-1,5-diol 1h 
 
149 mg from 206 mg 9h, 78 %, d.r. = 1:0.67; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.42 (2H, d, J = 8.4, Ar-H), 7.03 (2H, d, J = 8.4, Ar-H’), 6.04 (1H, d, J = 3.1, 
9-H), 5.89 (1H, dq, J = 3.1, 1.0, 10-H), 4.42 (1H, dd, J = 7.7, 6.8, 2-H), 3.62 – 3.35 (2H, m, 
6-H,H), 2.71 (1H, m, 4-H), 2.28 (3H, d, J = 1.0, 11-Me), 2.26 – 1.70 (4H, m, 3-H,H’, 5-
H,H’); minor  diastereomer: 7.43 (2H, d, J = 8.4, Ar-H), 7.12 (2H, d, J = 8.4, Ar-H’), 6.01 
(1H, d, J = 3.1, 9-H), 5.85 (1H, dq, J = 3.1, 1.0, 10-H), 4.26 (1H, dd, J = 10.4, 3.3, 2-H), 3.62 
– 3.35 (2H, m, 6-H,H’), 3.11 (1H, m, 4-H), 2.23 (3H, d, J = 1.0, 11-Me), 2.26 – 1.70 (4H, m, 
3-H’,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 154.8, 153.8, 152.0, 151.7, 143.3, 142.9, 
131.7, 130.0, 129.4, 120.1, 107.7, 106.5, 106.0, 105.9, 65.7, 65.0, 60.7, 60.5, 41.9, 41.7, 39.6, 
38.8, 38.1, 37.9, 13.6, 13.5; IR (thin film) νmax 3309 (br), 2920, 1563, 1486, 1432, 1408, 
1218, 1070, 1042, 1020, 1008, 889, 820, 784, 719, 565 cm
-1
; HRMS MNa
+ 
(C16H19O3NaBr) 
calcd 361.0415, found 361.0427 
 
 
1-(5-methylfuran-2-yl)-3-phenylpentane-1,5-diol 1i 
 
105 mg from 158 mg 9i, 73 %, d.r. = 1:0.65; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.35 – 7.14 (5H, m, Ar-H), 6.06 (1H, d, J = 3.2, 9-H), 5.90 (1H, m, 10-H), 4.44 
(1H, dd, J = 7.2, 7.2, 2-H), 3.61 – 3.39 (2H, m, 6-H,H), 2.71 (1H, dddd, J = 9.7, 9.7, 5.6, 5.6, 
4-H), 2.28 (3H, d, J = 0.7, 11-Me), 2.30 – 1.76 (4H, m, 3-H,H’, 5-H,H’); minor  
diastereomer: 7.35 – 7.14 (5H, m, Ar-H), 6.01 (1H, d, J = 3.1, 9-H), 5.85 (1H, m, 10-H), 4.29 
(1H, dd, J = 10.3, 3.3, 2-H), 3.61 – 3.39 (2H, m, 6-H,H’), 3.11 (1H, dddd, J = 10.1, 10.1, 5.5, 
4.5, 4-H), 2.23 (3H, d, J = 0.7, 11-Me), 2.30 – 1.76 (4H, m, 3-H’,H’, 5-H,H’); 13C NMR (75 
MHz, CDCl3) δ 154.0, 152.0, 144.2, 143.8, 128.6, 127.8, 127.6, 126.53, 126.50, 107.6, 106.4, 
106.0, 105.9, 65.9, 60.9, 42.2, 41.9, 39.8, 39.1, 38.9, 38.5, 13.6, 13.5; IR (thin film) νmax 3339 
(br), 2922, 1562, 1494, 1452, 1364, 1219, 1044, 1020, 1001, 965, 937, 784, 762, 700, 596 
cm
-1
; HRMS MNa
+
(C16H20O3Na) calcd 283.1310, found 283.1324. 
 
 
1-(5-Methylfuran-2-yl)-3-(p-tolyl)pentane-1,5-diol 1j 
 
126 mg from 145 mg 9j, 95 %, d.r. = 1:0.7; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.15 – 7.02 (4H, m, Ar-H), 6.05 (1H, d, J = 3.0, 9-H), 5.89 (1H, dq, J = 3.0, 
0.9, 10-H), 4.45 (1H, dd, J = 7.4, 7.4, 2-H), 3.61 – 3.38 (2H, m, 6-H,H), 2.67 (1H, m, 4-H), 
2.32 (3H, s, Ar-Me), 2.28 (3H, d, J = 0.9, 11-Me), 2.30 – 1.50 (4H, m, 3-H,H’, 5-H,H’); 
minor  diastereomer: 7.15 – 7.02 (4H, m, Ar-H), 6.01 (1H, d, J = 3.0, 9-H), 5.84 (1H, dq, J = 
3.0, 1.0, 10-H), 4.30 (1H, dd, J = 10.4, 2.5, 2-H), 3.61 – 3.38 (2H, m, 6-H,H’), 3.11 (1H, m, 
4-H), 2.32 (3H, s, Ar-Me), 2.23 (3H, d, J = 1.0, 11-Me), 2.30 – 1.50 (4H, m, 3-H’,H’, 5-
H,H’); 13C NMR (75 MHz, CDCl3) δ 155.2, 154.1, 151.9, 151.6, 141.1, 140.7, 136.03, 
135.98, 129.3, 127.7, 127.4, 107.6, 106.3, 105.98, 105.97, 65.9, 65.1, 61.1, 60.9, 42.3, 41.9, 
39.9, 39.1, 38.5, 38.1, 21.0, 13.6, 13.5; IR (thin film) νmax 3314 (br), 2920, 2882, 1513, 1044, 
1020, 784, 668, 631, 595, 533, 495 cm
-1
; HRMS MNa
+
(C17H22O3Na) calcd 297.1467, found 
297.1477.  
 
3-(4-chlorophenyl)-1-(5-methylfuran-2-yl)pentane-1,5-diol 1k 
 
106 mg from 163 mg 9k, 71 %, d.r. = 1:0.75; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.30 – 7.24 (2H, m, Ar-H), 7.09 (2H, d, J = 8.4, Ar-H’), 6.05 (1H, d, J = 3.0, 9-
H), 5.90 (1H, dq, J = 3.0, 1.0, 10-H), 4.42 (1H, m, 2-H), 3.60 – 3.35 (2H, m, 6-H,H’), 2.72 
(1H, dddd, J = 9.6, 9.6, 5.5, 5.5, 4-H), 2.32 ([3H, s, Ar-Me), 2.28 (3H, d, J = 1.0, 11-Me), 
2.28 – 1.70 (4H, m, 3-H,H’, 5-H,H’); minor  diastereomer: 7.30 – 7.24 (2H, m, Ar-H), 7.16 
(2H, d, J = 8.4, Ar-H’), 6.01 (1H, d, J = 3.1, 9-H), 5.85 (1H, dq, J = 3.1, 1.0, 10-H), 4.26 (1H, 
m, 2-H), 3.60 – 3.35 (2H, m, 6-H,H’), 3.11 (1H, m, 4-H), 2.32 (3H, s, Ar-Me), 2.23 (3H, d, J 
= 1.0, 11-Me), 2.28 – 1.70 (4H, m, 3-H’,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 154.9, 
153.9, 151.9, 151.6, 142.9, 142.5, 131.9, 129.2, 128.9, 128.6, 107.5, 106.4, 106.0, 105.9, 
65.4, 64.9, 60.33, 60.29, 42.0, 41.4, 39.6, 38.4, 37.8, 37.5, 13.54, 13.45; IR (thin film) νmax 
3323 (br), 2922, 1489, 1434, 1412, 1219, 1090, 1043, 1013, 965, 937, 891, 826, 784, 721, 
702, 566, 500 cm
-1
; HRMS MNa
+
(C16H19O3NaCl) calcd 317.0920, found 317.0936.  
 
General Procedure for the acid catalysed cyclisation of diols of 1a-k to form 
disubstituted tetrahydropyrans 3a-k 
 
Diol 1a-k (0.22 mmol) was dissolved in acetonitrile (2 mL). Quadrapure™ polymer 
supported sulfonic acid (20 mg, 5.0 mmol/g loading) was then added to the reaction mixture. 
The reaction mixture was stirred gently at room temperature for 10 hrs. Upon completion, the 
reaction mixture was filtered and the polymer beads washed three times with acetonitrile (5 
mL). The solution was then concentrated under reduced pressure.  The crude product was 
purified by column chromatography on silica gel (using a solvent gradient from petroleum 
ether to 1:1 petroleum ether - diethyl ether) to furnish the product 3a-k. Only peaks 
corresponding to the major isomer are reported, except in the case of 3a, whose syn and anti  
diastereomers were separable by column chromatography (following the sodium 
hydride/tosyl chloride promoted cyclization, see below). Crystals of 3e and 3g for x-ray 
diffraction were obtained by slow evaporation of ethyl acetate solutions placed in glass vials 
plugged with cotton wool.  
 
(±)-(2S,4R)-2-(furan-2-yl)-4-phenyltetrahydro-2H-pyran syn-3a 
38 mg of syn/anti-3a, d.r. = 16:1, was afforded from 54 mg 1a, 76 %. Data for syn-3a: 
1
H 
NMR (300 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.8, 0.8, 11-H), 7.38 – 7.20 (5H, m, Ar-H), 6.34 
(1H, dd, J = 3.3, 1.8, 10-H), 6.29 (1H, ddd, J = 3.3, 0.8, 0.8, 9-H), 4.56 (1H, dd, J = 11.0, 2.6, 
2-H), 4.24 (1H, ddd, J = 11.6, 4.3, 1.8, 6-eq), 3.77 (1H, ddd, J = 11.6, 11.6, 2.8, 6-ax), 2.92 
(1H, dddd, 11.7, 11.7, 4.3, 4.3, 4-H), 2.16 – 1.78 (4H, m, 3-H,H’, 5-H,H’); 13C NMR (75 
MHz, CDCl3) δ 154.6, 145.2, 142.2, 128.6, 126.8, 126.5, 110.1, 106.3, 73.1, 68.6, 41.6, 37.1, 
33.1; IR (thin film) νmax 2938, 2917, 2844, 1495, 1452, 1374, 1352, 1252, 1227, 1194, 1169, 
1145, 1123, 1079, 1044, 1030, 1012, 997, 958, 942, 927, 913, 884, 876, 840, 806, 736, 698, 
629, 599, 547, 531 cm
-1
; HRMS M
+
(C15H16O2) calcd 228.1150, found 228.1142.  
 
 
 
 
(±)-(2R,4R)-2-(Furan-2-yl)-4-phenyltetrahydro-2H-pyran anti-3a 
 
1
H NMR (300 MHz, CDCl3) δ 7.45 (1H, d, J = 1.7, 11-H), 7.39 – 7.21 (5H, m, Ar-H), 6.41 
(1H, dd, J = 3.2, 1.7, 10-H), 6.37 (1H, ddd, J = 3.2, 0.8, 0.8, 9-H), 5.09 (1H, dd, J = 5.2, 2.7, 
2-H), 3.87 (1H, ddd, J = 11.3, 4.2, 3.5, 6-H), 3.73 (1H, ddd, J = 11.3, 11.0, 2.8, 6-H’), 3.13 
(1H, dddd, J = 11.1, 10.9, 4.3, 4.2, 4-H), 2.34 (1H, dddd, J = 13.7, 4.2, 2.7, 1.7, 3-H), 2.19 
(1H, ddd, J = 13.7, 11.1, 5.2, 3-H’), 1.94 (1H, dddd, J = 13.4, 11.0, 10.9, 4.2, 5-H), 1.82 (1H, 
m, 5-H’); 13C NMR (75 MHz, CDCl3) δ 154.1, 145.2, 142.1, 128.6, 126.9, 126.4, 110.1, 
108.0, 69.1, 62.7, 36.4, 34.1, 32.9; IR (thin film) νmax 2959, 2948, 2926, 2897, 2873, 1498, 
1452, 1439, 1431, 1377, 1351, 1341, 1310, 1269, 1241, 1229, 1181, 1174, 1158, 1146, 1119, 
1110, 1093, 1080, 1060, 1027, 1013, 1005, 996, 952, 921, 898, 880, 829, 810, 799, 768, 739, 
700, 669, 617, 599, 574, 534 cm
-1
; HRMS M
+
(C15H16O2) calcd 228.1150, found 228.1151. 
  
(±)-(2S,4R)-4-(4-Chlorophenyl)-2-(furan-2-yl)tetrahydro-2H-pyran 3b 
 
38 mg from 51 mg 1a, 80%, 
1
H NMR (300 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.8, 0.8, 11-H), 
7.30 (2H, d, J = 8.5, Ar-H), 7.19 (2H, d, J = 8.5, Ar-H’), 6.34 (1H, dd, J = 3.3, 1.8, 10-H), 
6.29 (1H, d, J = 3.3, 8-H), 4.54 (1H, dd, J = 11.1, 2.5, 2-H), 4.23 (1H, ddd, J = 11.6, 4.1, 2.0, 
6-H-eq), 3.68, (1H, ddd, J = 11.6, 11.4, 3.3, 6-H’-ax), 2.90 (1H, dddd, J = 11.4, 11.4, 4.4, 4.4, 
4-H), 2.09 (1H, m, 3-H), 1.97 (1H, m, 3-H’), 1.94 – 1.75 (2H, m, 5-H,H’); 13C NMR (75 
MHz, CDCl3) δ 154.4, 143.6, 142.2, 132.1, 128.7, 128.1, 110.1, 106.4, 73.0, 68.4, 41.0, 37.0, 
33.0; IR (thin film) νmax  2917, 2844, 1491, 1441, 1410, 1372, 1334, 1252, 1226, 1169, 1145, 
1124, 1078, 1043, 1012, 998, 960, 943, 927, 884, 877, 843, 824, 803, 770, 736, 634, 599, 592 
cm
-1
; HRMS M
+
(C15H15O2Cl) calcd 262.0761, found 262.0771. 
 
(±)-(2S,4R)-2-(furan-2-yl)-4-(4-methoxyphenyl)tetrahydro-2H-pyran 3c 
 
54 mg from 96 mg 1c, 60 %, 
1
H NMR (300 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.8, 0.8, 11-H), 
7.19 (2H, d, J = 8.6, Ar-H), 6.88 (2H, d, J = 8.7, Ar-H’), 6.34 (1H, dd, J = 3.2, 1.8, 10-H), 
6.29 (1H, d, J = 3.2, 9-H), 4.55 (1H, dd, J = 11.1, 2.4, 2-H), 4.23 (1H, ddd, J = 11.5, 4.2, 1.9, 
3-H), 3.80 (3H, s, Ar-OMe), 3.75 (1H, m, 6-H’), 2.87 (1H, m, 4-H), 2.13 – 1.75 (4H, m, 3-
H,H’, 5-H,H’); selected peaks for minor diastereomer: 7.45 (1H, d, J = 1.7, 11-H), 6.40 (1H, 
dd, J = 3.2, 1.7, 10-H), 6.36 (1H, m, 9-H), 5.07 (1H, dd, J = 5.0, 3.2, 2-H), 3.08 (1H, m, 4-H); 
13
C NMR (75 MHz, CDCl3) δ 158.1, 154.6, 142.2, 137.4, 127.6, 113.9, 110.1, 106.3, 73.0, 
68.6, 55.2, 40.7, 37.3, 33.3; IR (thin film) νmax 2919, 2837, 1610, 1583, 1512, 1461, 1441, 
1371, 1351, 1304, 1288, 1245, 1178, 1146, 1123, 1078, 1034, 1011, 998, 959, 943, 927, 848, 
828, 806, 787, 753, 599, 547, 531, 504 cm
-1
; HRMS M
+
(C16H18O3) calcd 258.1256, found 
258.1244. 
 
(±)-(2S,4R)-2-(furan-2-yl)-4-(p-tolyl)tetrahydro-2H-pyran 3d 
 
48 mg from 62 mg 1d, 83 %, 
1
H NMR (300 MHz, CDCl3) δ 7.48 (1H, m, 11-H), 7.26 (4H, 
m, Ar-H), 6.43 (1H, dd, J = 3.2, 1.7, 10-H), 6.39 (1H, d, J = 3.2, 9-H), 4.64 (1H, dd, J = 10.9, 
2.5, 2-H), 4.33 (1H, ddd, J = 11.6, 4.3, 1.4, 6-H), 3.83 (1H, ddd, J = 11.6, 11.6, 2.6, 6-H’), 
2.96 (1H, dddd, J = 11.7, 11.7, 4.2, 4.2, 4-H), 2.44 (3H, s, Ar-Me), 2.25 – 2.05 (2H, m, 3-
H,H’), 2.04 – 1.83 (2H, m, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 154.3, 142.0, 141.9, 
135.7, 129.0, 126.4, 109.8, 106.0, 72.8, 68.3, 40.8, 37.0, 33.0, 20.7; IR (thin film) νmax 2916, 
2847, 1514, 1440, 1373, 1349, 1251, 1226, 1193, 1169, 1142, 1121, 1108, 1078, 1039, 1011, 
998, 959, 944, 924, 910, 875, 846, 804, 797, 734, 587, 600, 587, 600, 541, 505 cm
-1
; HRMS 
M
+
(C16H18O2) calcd 242.1307, found 242.1299. 
 
 
(±)-(2S,4R)-4-(3,4-Dimethoxyphenyl)-2-(furan-2-yl)tetrahydro-2H-pyran 3e 
 
75 mg from 84 mg 1e, 95 %, m.p. = 87.5-88.5 C. 1H NMR (300 MHz, CDCl3) δ 7.39 (1H, 
dd, J = 1.8, 0.8, 11-H), 6.86 – 6.77 (3H, m, Ar-H), 6.34 (1H, dd, J = 3.3, 1.8, 10-H), 6.29 
(1H, d, J = 3.3, 9-H), 4.54 (1H, dd, J = 11.1, 2.4, 2-H), 4.23 (1H, ddd, J = 11.5, 4.2, 1.8, 6-H-
eq), 3.89 (3H, s, Ar-OMe), 3.87 (3H, s, Ar-OMe’), 3.75 (1H, ddd, J = 11.5, 11.5, 3.3, 6-H’-
ax), 2.87 (1H, dddd, J = 11.6, 11.6, 4.3, 4.3, 4-H), 2.10 (1H, m, 3-H), 1.99 (1H, m, 3-H’), 
1.95 – 1.75 (2H, m, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 154.6, 148.8, 147.5, 142.2, 137.9, 
118.4, 111.2, 110.03, 109.96, 106.3, 73.0, 68.5, 55.8, 55.8, 41.2, 37.3, 33.3; IR (thin film) 
νmax 2933, 2835, 1515, 1463, 1418, 1259, 1242, 1190, 1142, 1120, 1078, 1026, 1013, 951, 
912, 882, 808, 762, 729, 638, 599, 541 cm
-1
; HRMS M
+
(C17H20O4) calcd 288.1362, found 
288.1359. 
 
(±)-(2S,4R)-4-(4-Bromophenyl)-2-(furan-2-yl)tetrahydro-2H-pyran 3f 
 
80 mg from 88 mg 1f, 96 %, 
1
H NMR (300 MHz, CDCl3) δ 7.46 (2H, d, J = 8.5, Ar-H), 7.40 
(1H, dd, J = 1.8, 0.8, 11-H), 7.14 (2H, d, J = 8.5, Ar-H), 6.35 (1H, dd, J = 3.3, 1.8, 10-H), 
6.30 (1H, d, J = 3.3, 9-H), 4.55 (1H, dd, J = 11.0, 2.4, 2-H), 4.24 (1H, ddd, J = 11.5, 4.1, 2.0, 
6-H-eq), 3.75 (1H, ddd, J = 11.5, 11.4, 3.7, 6-H’-ax), 2.88 (1H, dddd, J = 11.4, 11.4, 4.3, 4.3, 
4-H), 2.09 (1H, m, 3-H), 2.00 (1H, m, 3-H’), 1.93 – 1.75 (2H, m, 5-H,H’); 13C NMR (75 
MHz, CDCl3) δ 154.3, 144.1, 142.2, 131.6, 128.5, 120.1, 110.1, 106.4, 72.9, 68.3, 41.0, 36.9, 
32.9; IR (thin film) νmax 2917, 2846, 1488, 1441, 1252, 1227, 1169, 1145, 1122, 1075, 1044, 
1008, 959, 927, 911, 884, 842, 820, 768, 732, 673, 599, 555 cm
-1
; HRMS M
+
(C15H15O2Br) 
calcd 306.0255, found 306.0268. 
 
(±)-(2S,4R)-2-(Furan-2-yl)-4-(2,4,5-trimethoxyphenyl)tetrahydro-2H-pyran 3g 
 
107 mg from 122 mg 1g, 93 %, 
1
H NMR (400 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.8, 0.7, 11-
H), 6.79 (1H, s, Ar-H), 6.54 (1H, s, Ar-H’), 6.33 (1H, dd, J = 3.2, 1.8, 10-H), 6.28 (1H, d, J = 
3.2, 9-H), 4.57 (1H, dd, J = 11.4, 2.2, 2-H), 4.22 (1H, ddd, J = 11.5, 4.3, 1.2, 6-H), 3.87 (3H, 
s, OMe), 3.85 (3H, s, OMe), 3.82 (3H, s, OMe), 3.78 (1H, ddd, J = 12.0, 11.5, 2.2, 6-H’), 
3.32 (1H, dddd, J = 12.1, 11.8, 3.8, 3.7, 4-H), 2.05 (1H, dddd, J = 12.3, 3.7, 2.2, 2.0, 3-H), 
1.94 (1H, ddd, J = 12.3, 11.8, 11.4, 3-H’), 1.87 (1H, ddd, J = 12.3, 12.0, 4.3, 5-H), 1.74 (1H, 
m, 5-H’); 13C NMR (100 MHz, CDCl3) δ 154.8, 150.8, 147.7, 142.9, 142.1, 124.8, 111.0, 
110.0, 106.2, 97.5, 73.2, 68.7, 55.7, 58.3, 56.1, 36.1, 33.8, 31.9; IR (thin film) νmax 2937, 
2835, 1508, 1463, 1440, 1397, 1372, 1316, 1217, 1243, 1229, 1202, 1148, 1126, 1078, 1033, 
1014, 982, 957, 943, 927, 883, 858, 814, 733 cm
-1
; HRMS M
+
 (C18H22O5): calcd 318.1467, 
found 318.1458. 
 
(±)-(2S,4R)-4-(4-bromophenyl)-2-(5-methylfuran-2-yl)tetrahydro-2H-pyran 3h 
 
80 mg from 121 mg 1h, 70 %, 
1
H NMR (300 MHz, CDCl3) δ 7.45 (2H, d, J = 8.4, Ar-H), 
7.14 (2H, d, J = 8.4, Ar-H), 6.16 (1H, d, J = 3.1, 9-H), 5.91 (1H, dq, J = 3.1, 0.9, 19-H), 4.47 
(1H, dd, J = 10.7, 2.8, 2-H), 4.23 (1H, ddd, J = 11.6, 4.2, 2.0, 6-H-eq), 3.74 (1H, ddd, J = 
11.6, 11.4, 3.5, 6-H’-ax), 2.87 (1H, dddd, J = 11.3, 11.3, 4.6, 4.6, 4-H), 2.29 (3H, d, J = 0.9, 
11-Me), 2.09 – 1.93 (2H, m, 3-H,H’), 1.92 – 1.74 (2H, m, 5-H,H’); 13C NMR (75 MHz, 
CDCl3) δ 152.6, 152.1, 144.2, 131.6, 128.6, 120.1, 107.4, 106.0, 73.0, 68.4, 41.2, 36.8, 33.0, 
13.6; IR (thin film) νmax 2944, 2918, 2843, 1489, 1440, 1373, 1251, 1221, 1075, 1050, 1009, 
964, 821, 786, 669, 535, 500 cm
-1
; HRMS M
+
(C16H17O2Br) calcd 320.0412, found 320.0403. 
 
(±)-(2S,4R)-2-(5-methylfuran-2-yl)-4-phenyltetrahydro-2H-pyran 3i 
 
65 mg from 79 mg 1i, 88 %, 
1
H NMR (300 MHz, CDCl3) δ 7.35 – 7.18 (5H, m, Ar-H), 6.15 
(1H, d, J = 3.1, 9-H), 5.89 (1H, dq, J = 3.1, 0.9, 10-H), 4.47 (1H, dd, J = 10.3, 3.2, 2-H), 4.22 
(1H, ddd, J = 11.6, 4.4, 1.7 6-H-eq), 3.73 (1H, ddd, J = 11.6, 11.6, 2.7, 6-H’-ax), 2.88 (1H, 
dddd, J = 11.7, 11.7, 4.5, 4.5, 4-H), 2.27 (3H, d, J = 0.9, 11-Me), 2.10 – 1.94 (2H, m, 3-
H,H’), 1.93 – 1.74 (2H, m, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 152.8, 152.0, 145.3, 
128.6, 126.8, 126.5, 107.3, 106.0, 73.1, 68.5, 41.7, 36.9, 33.1, 13.6; IR (thin film) νmax 2920, 
2848, 1496, 1452, 1374, 1251, 1220, 1123, 1078, 1050, 1022, 1012, 964, 940, 907, 786, 757, 
727, 698, 668, 647 cm
-1
; HRMS M
+
(C16H18O2) calcd 242.1307, found 242.1297. 
 
(±)-(2S,4R)-2-(5-methylfuran-2-yl)-4-(p-tolyl)tetrahydro-2H-pyran 3j 
 
63 mg from 78 mg 1j, 86 %, 
1
H NMR (300 MHz, CDCl3) δ 7.21 – 7.12 (4H, m, Ar-H), 6.17 
(1H, d, J = 3.1, 9-H), 5.91 (1H, dq, J = 3.1, 0.9, 10-H), 4.49 (1H, dd, J = 10.5, 3.0, 2-H), 4.24 
(1H, ddd, J = 11.6, 4.3, 1.7, 6-H-eq), 3.75 (1H, ddd, J = 11.6, 11.6, 2.8, 6-H’-ax), 2.88 (1H, 
dddd, J = 11.6, 11.6, 4.5, 4.5, 4-H), 2.35 (3H, s, Ar-Me), 2.30 (3H, d, J = 0.9, 11-Me), 2.12 – 
1.76 (4H, m, 3-H,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 152.8, 152.0, 142.3, 136.0, 
129.2, 126.6, 107.3, 105.9, 73.0, 68.5, 41.2, 37.0, 33.1, 21.0, 13.6; IR (thin film) νmax 2919, 
2847, 1566, 1515, 1441, 1372, 1250, 1221, 1164, 1122, 1108, 1077, 1049, 1020, 1011, 964, 
940, 911, 846, 814, 781, 751, 732, 719, 643, 589, 568, 540, 515 cm
-1
; HRMS M
+
(C17H20O2) 
calcd 256.1463, found 256.1457. 
 
 
(±)-(2S,4R)-4-(4-chlorophenyl)-2-(5-methylfuran-2-yl)tetrahydro-2H-pyran 3k 
 
32 mg from 50 mg 1k, 68 %, 
1
H NMR (300 MHz, CDCl3) δ7.30 (2H, d, J = 8.5, Ar-H), 7.19 
(2H, d, J = 8.5, Ar-H’), 6.16 (1H, d, J = 3.2, 9-H), 5.91 (1H, dq, J = 3.2, 1.1, 10-H), 4.48 (1H, 
dd, J = 10.6, 2.8, 2-H), 4.23 (1H, ddd, J = 11.5, 4.1, 1.9, 6-H-eq), 3.74 (1H, ddd, J = 11.5, 
11.4, 3.0, 6-H’-ax), 2.88 (1H, dddd, J = 11.4, 11.4, 4.6, 4.6, 4-H), 2.29 (3H, d, J = 0.8, 11-
Me), 2.10 – 1.74 (4H, m, 3-H,H’, 5-H,H’); 13C NMR (75 MHz, CDCl3) δ 152.6, 152.0, 143.7, 
132.1, 128.6, 128.1, 107.4, 106.0, 72.9, 68.3, 41.1, 36.8, 33.0, 13.6; IR (thin film) νmax 2942, 
2919, 2842, 1566, 1492, 1441, 1410, 1372, 1333, 1251, 1221, 1124, 1084, 1050, 1012, 965, 
940, 912, 843, 826, 787, 635, 620, 565, 536 cm
-1
; HRMS M
+
(C16H17O2Cl) calcd 276.0917, 
found 276.0905. 
 
Procedure for the sodium hydride and tosyl chloride mediated cyclization of diol of 1a 
to form 3a without equilibration 
 
Diol 1a (300 mg, 1.22 mmol, 1 equiv.) was dissolved in anhydrous tetrahydrofuran (10 mL) 
under nitrogen. To this was added sodium hydride (60% suspension in mineral oil, 487 mg, 
12.2 mmol, 10 equiv.), which caused effervescence, and the mixture was stirred at room 
temperature for 30 minutes. p-Toluenesulfonyl chloride (465 mg, 2.44 mmol, 2 equiv.) was 
added in one portion. The mixture was stirred at room temperature overnight after which 
TLC analysis indicated that the reaction had gone to completion. The reaction was quenched 
by adding to 2.0 M aqueous sodium hydroxide solution (40 mL) with stirring. The mixture 
was extracted with ethyl acetate (3 x 30 mL) and the combined organic phases were washed 
with water (2 × 50 mL) and brine (50 mL). The organic phase was then dried over 
magnesium sulfate and concentrated under reduced pressure. The diastereomeric ratio of 
tetrahydropyrans in the crude material was 1:0.7 (by 
1
H NMR analysis). The crude material 
was purified by careful column chromatography on silica gel (Merck 9385 grade) eluting 
with a gradient from petrol ether to 98:2 petrol ether : diethyl ether then to 95:5 petrol ether : 
diethyl ether. Fractions containing mixtures of the two diastereomers were recombined and 
chromatography was repeated. Chromatography was carried out thrice in total to afford two 
diastereomerically pure fractions of syn-3a (27 mg, 10%) and anti-3a (46 mg, 17%) as well 
as a diastereomeric mixed fraction (103 mg, 37%).  
 
General Procedure for the reduction of ketodiesters 8a-k to form triols 4a-k 
 
Solid lithium aluminium hydride (380 mg, 10.0 mmol, 10 equiv.) was suspended in 
anhydrous tetrahydrofuran (15 mL) under dry nitrogen. This was cooled to −15 °C before 
crude keto-diester 8a-k (1.00 mmol, 1 equiv.) in anhydrous tetrahydrofuran (10 mL) was 
added dropwise. The reaction was then stirred at room temperature for 20 minutes after 
which TLC analysis indicated the reaction had gone to completion. The reaction was then 
quenched by the addition of diethyl ether (20 mL) followed by the slow dropwise addition of 
a 4:1 mixture of diethyl ether and acetone (20 mL) at −15 °C. The reaction mixture was then 
diluted with ethyl acetate (60 mL) and washed with water (150 mL) and 2M sodium 
hydroxide solution (250 mL). The combined aqueous phase was extracted with ethyl acetate 
(6 × 60 mL). The combined organic phase was then washed with brine (3 × 100 mL) before 
being dried over magnesium sulfate. The solution was then concentrated under reduced 
pressure. The crude product was purified by column chromatography using silica gel and a 
solvent gradient from dichloromethane reaching 97:3 dichloromethane-methanol. Following 
removal of solvent under reduced pressure, the product 4a-k was isolated as a mixture of 
diastereomers. 
1
H NMR data for each diastereomer of a mixture are generally listed 
separately. In the case of 4e, the 1:1 ratio prevented the assignment of peaks to each 
diastereomer and the peaks are provided as a single list. In the case of 4b, the diastereomers 
of which were separated by recrystallization, the data for each are listed separately. 
Separation of syn and anti-4b was achieved through repeated recrystallisation from hot (ca. 
50 C) ethyl acetate solutions which were cooled in the refrigerator (ca. 3 C).  
 
1-(Furan-2-yl)-4-(hydroxymethyl)-3-phenylpentane-1,5-diol 4a 
 
45 mg from 142 mg 7a, 23 % 2 steps, d.r. = 1:0.8; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.30 (2H, d, J = 8.5, Ar-H), 7.19 (2H, d, J = 8.5, Ar-H’), 6.16 (1H, d, J = 3.2, 
9-H), 5.91 (1H, dq, J = 3.2, 1.1, 10-H), 4.48 (1H, dd, J = 10.6, 2.8, 2-H), 4.23 (1H, ddd, J = 
11.5, 4.1, 1.9, 6-H-eq), 3.74 (1H, ddd, J = 11.5, 11.4, 3.0, 6-H’-ax), 2.88 (1H, dddd, J = 11.4, 
11.4, 4.6, 4.6, 4-H), 2.29 (3H, d, J = 0.8, 11-Me), 2.10 – 1.74 (4H, m, 3-H,H’, 5-H,H’); minor 
diastereomer: 7.33 – 7.16 (5H, m, Ar-H, 11-H), 7.10 – 7.02 (1H, m, Ar-H’), 6.23 (1H, dd, J = 
3.2, 1.8, 10-H), 6.04 (1H, d, J = 3.2, 9-H), 4.18 (1H, dd, J = 10.8, 1.6, 2-H), 3.94 – 3.10 (7H, 
m, 4-H,6-H,H’,7-H,H’,OH,OH), 2.59 – 1.60 (4H, m, 3-H,H’,5-H,OH); 13C NMR (75 MHz, 
CDCl3) δ 157.1, 155.4, 142.40, 142.36, 142.1, 141.6, 128.6, 128.5, 128.3, 128.1, 126.6, 
110.1, 110.0, 107.1, 105.2, 65.9, 64.9, 63.7, 63.4, 62.3, 46.6, 40.1, 38.9, 38.6; IR (thin film) 
νmax 3317(br), 2889, 1494, 1453, 1146, 1000, 963, 907, 812, 727, 701, 646, 598, 492, 456 cm
-
1
 
 
(±)-(1S,3S)-3-(4-chlorophenyl)-1-(furan-2-yl)-4-(hydroxymethyl)pentane-1,5-diol anti-4b 
 
3.92 g of syn/anti-4b were obtained from 3.80 g 7b (77 %, 2 steps), d.r. = 1:0.8 (in favour of 
syn-4b) . The diastereoisomers of 4b were separated by repeated recrystallization from ethyl 
acetate. Data for anti-4b: 
1
H NMR (400 MHz, CD3CN) δ 7.35 (1H, dd, J = 1.8, 0.8, 11-H), 
7.32 (2H, d, J = 8.5, Ar-H), 7.22 (2H, d, J = 8.5, Ar-H’), 6.30 (1H, dd, J = 3.2, 1.8, 10-H), 
6.13 (1H, ddd, J = 3.2, 0.8, 0.8, 9-H), 4.06 (1H, ddd, J = 10.7, 5.7, 2.6, 2-H), 3.78 – 3.65 (1H, 
m, 6-H,H’), 3.39 (1H, ddd, J = 10.6, 4.9, 4.1, 7-H), 3.26 (1H, m, 2-OH), 3.25 (1H, ddd, J = 
10.6, 7.0, 5.4, 7-H’), 3.11 (1H, ddd, J = 12.6, 9.0, 3.6, 4-H), 2.92 (1H, dd, J = 5.2, 5.2, 6-OH), 
2.74 (1H, dd, J = 5.4, 4.9, 7-OH), 2.25 (1H, ddd, J = 14.1, 10.7, 3.6, 3-H), 1.99 (1H, ddd, J = 
14.1, 12.6, 2.6, 3-H’) (obscured by residual MeCN in CD3CN), 1.78 (1H, m, 5-H); 
13
C NMR 
(100 MHz, CD3CN) δ 159.0, 143.0, 142.5, 132.1, 131.2, 129.0, 111.0, 105.9, 65.1, 62.8, 62.1, 
48.4, 40.0, 39.4; IR (thin film) νmax 3363(br), 3212, 2932, 2897, 1488, 1453, 1412, 1360, 
1331, 1226, 1147, 1119, 1082, 1068, 1048, 1013, 996, 966, 875, 847, 761, 739, 668, 638, 
617, 598, 569, 543, 513 cm
-1
; HRMS MNa
+
(C16H19O4ClNa) calcd 333.0870, found 333.0860. 
 
(±)-(1R,3S)-3-(4-chlorophenyl)-1-(furan-2-yl)-4-(hydroxymethyl)pentane-1,5-diol syn-4b 
 
1
H NMR (400 MHz, CD3CN) δ 7.45 (1H, dd, J = 1.8, 0.8, 11-H), 7.33 (2H, d, J = 8.5, Ar-H), 
7.12 (2H, d, J = 8.5, Ar-H’), 6.38 (1H, dd, J = 3.2, 1.8, 10-H), 6.21 (1H, d, J = 3.2, 9-H), 4.18 
(1H, ddd, J = 9.8, 5.2, 5.1, 2-H), 3.73 – 3.65 (1H, m, 6-H,H’), 3.36 (1H, ddd, J = 10.6, 4.6, 
4.2, 7-H), 3.28 (1H, d, J = 5.2, 2-OH), 3.14 (1H, ddd, J = 10.7, 6.8, 5.1, 7-H’), 2.93 (1H, dd, J 
= 5.0, 5.0, 6-OH), 2.72 (1H, dd, J = 5.1, 4.6, 7-OH), 2.58 (1H, ddd, J = 11.1, 8.8, 4.1, 4-H), 
2.43 (1H, ddd, J = 13.7, 9.8, 4.1, 3-H), 2.09 (1H, ddd, J = 13.4, 11.1, 5.1, 3-H’), 1.78 (1H, m, 
5-H); 
13
C NMR (100 MHz, CD3CN) δ 157.4, 143.2, 142.9, 132.1, 130.9, 129.0, 110.9, 107.4, 
66.1, 62.4, 62.1, 48.3, 40.5, 39.4 ; IR (thin film) νmax 3348(br), 2891, 1490, 1411, 1331, 1235, 
1146, 1090, 1047, 1012, 964, 946, 908, 884, 859, 814, 727, 645, 598, 510 cm
-1
; HRMS 
MNa
+
(C16H19O4ClNa) calcd 333.0870, found 333.0860.  
 
 
1-(Furan-2-yl)-4-(hydroxymethyl)-3-(4-methoxyphenyl)pentane-1,5-diol 4c 
 
101 mg from 231 mg 7c, 33 % 2 steps, d.r. = 1:0.65; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.33 (1H, dd, J = 1.9, 0.7, 11-H), 6.95 (2H, d, J = 8.6, Ar-H), 6.84 – 6.77 (2H, 
m, Ar-H’), 6.28 (1H, dd, J = 3.2, 1.9, 10-H), 6.13 (1H, d, J = 3.2, 9-H), 4.33 (1H, dd, J = 8.8, 
5.3, 2-H), 3.92 – 3.71 (2H, m, 7-H,H’), 3.76 (3H, s, Ar-OMe), 3.58 – 3.01 (6H, m, 4-H,6-
H,H’, 3 x OH), 2.54 – 1.70 (3H, m, 3-H,H’,5-H); minor  diastereomer: 7.25 (1H, m, 11-H), 
7.09 (2H, d, J = 8.6, Ar-H), 6.84 – 6.77 (2H, m, Ar-H’), 6.23 (1H, dd, J = 3.2, 1.8, 10-H), 
6.06 (1H, d, J = 3.2, 9-H), 4.20 (1H, dd, J = 11.0, 1.6, 2-H), 3.92 – 3.71 (2H, m, 7-H,H’), 
3.76 (3H, s, Ar-OMe), 3.58 – 3.01 (6H, m, 4-H,6-H,H’, 3 x OH), 2.54 – 1.70 (3H, m, 3-
H,H’,5-H); 13C NMR (75 MHz, CDCl3) δ 158.1, 157.2, 155.4, 142.1, 141.6, 134.23, 134.19, 
129.2, 128.9, 114.0, 113.9, 110.1, 110.0, 107.1, 105.2, 66.0, 64.9, 63.8, 63.7, 62.6, 55.2, 50.6, 
46.7, 39.3, 38.7, 38.1; IR (thin film) νmax 3311(br), 2944, 2887, 2834, 1609, 1509, 1440, 
1301, 1244, 1177, 1146, 1008, 963, 910, 883, 828, 736, 668, 649, 618, 598, 556 cm
-1
; HRMS 
MNa
+
(C17H22O5Na) calcd 329.1365, found 329.1361. 
 
1-(Furan-2-yl)-4-(hydroxymethyl)-3-(p-tolyl)pentane-1,5-diol 4d 
 
103 mg from 250 mg 7d, 30 % 2 steps, d.r. = 1:0.75; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.31 (1H, dd, J = 1.7, 0.6, 11-H), 7.10 – 7.06 (2H, m, Ar-H), 6.92 (2H, d, J = 
8.0, Ar-H’), 6.27 (1H, dd, J = 3.1, 1.7, 10-H), 6.14 (1H, d, J = 3.1, 9-H), 4.33 (1H, dd, J = 
8.8, 5.4, 2-H), 3.90 – 3.00 (7H, m, 4-H,6-H,H’,7-H,H’,OH,OH), 2.54 – 1.70 (4H, m, 3-
H,H’,5-H,OH), 2.30 (3H, s, a-Ar-Me); minor  diastereomer: 7.24 (1H, dd, J = 1.7, 0.7, 11-H), 
7.10 – 7.06 (4H, m, Ar-H), 6.22 (1H, dd, J = 3.1, 1.7, 10-H), 6.06 (1H, d, J = 3.1, 9-H), 4.19 
(1H, dd, J = 10.9, 1.5, 2-H), 3.90 – 3.00 (7H, m, 4-H,6-H,H’,7-H,H’,OH,OH), 2.54 – 1.70 
(4H, m, 3-H,H’,5-H,OH), 2.30 (3H, s, Ar-Me); 13C NMR (75 MHz, CDCl3) δ 157.2, 155.4, 
142.1, 141.6, 139.2, 139.1, 136.00, 135.95, 129.3, 129.2, 128.1, 127.9, 110.04, 109.98, 107.0, 
105.2, 65.9, 64.9, 63.62, 63.58, 63.4, 62.2, 46.7, 46.6, 39.8, 38.6, 38.5, 21.0; IR (thin film) 
νmax 3315 (br), 2922, 2889, 1512, 1435, 1147, 1010, 964, 909, 884, 814, 730, 632, 599, 533 
cm
-1
; HRMS MNa
+
(C17H22O4Na) calcd 313.1416, found 313.1407. 
 
3-(3,4-Dimethoxyphenyl)-1-(furan-2-yl)-4-(hydroxymethyl)pentane-1,5-diol 4e 
 
1.25 g from 1.13 g 7e, 85 % 2 steps, d.r. = 1:1; 
1
H NMR (400 MHz, CD3CN) δ 1:1 mixture of  
diastereomers, peaks could not be assigned to individual  diastereomers (a and b) 7.33 (1H, 
dd, J = 1.7, 0.6, a/b-11-H), 7.26 (1H, m, b/a-11-H), 6.80 – 6.70 (2H + 2H, a+b-Ar-H), 6.61 – 
6.35 (1H + 1H, a+b-Ar-H’), 6.29 (1H, dd, J = 3.1, 1.7, a/b-10-H), 6.24 (1H, dd, J = 3.2, 1.7, 
b/a-10-H), 6.15 (1H, d, J = 3.1, a/b-9-H), 6.07 (1H, d, J = 3.2, b/a-9-H), 4.36 (1H, dd, J = 8.7, 
5.3, a/b-2-H), 4.24 (1H, dd, J = 11.0, 1.5, b/a-2-H), 4.00 – 3.72 (8H + 8H, m, a+b-6-H,H’,2 x 
OMe), 3.65 – 3.01 (6H + 6H, m, a+b-7-H,H’,4-H,3 x OH), 2.60 – 1.70 (3H + 3H, m, a+b-3-
H,H’,5-H); 13C NMR (100 MHz, CD3CN) δ 157.1, 155.5, 148.9, 148.7, 147.5, 142.1, 141.6, 
134.86, 134.85, 120.3, 119.9, 111.2, 111.09, 110.08, 110.04, 107.0, 105.2, 66.0, 65.0, 64.0, 
63.9, 63.6, 62.6, 55.84, 55.78, 46.8, 39.7, 38.7, 38.6; IR (thin film) νmax 3330(br), 2934, 2835, 
1590, 1511, 1493, 1420, 1323, 1255, 1233, 1139, 1022, 914, 884, 861, 808, 764, 728, 646, 
598 cm
-1
; HRMS MNa
+
(C18H24O6Na) calcd 359.1471, found 359.1455. 
 
3-(4-Bromophenyl)-1-(furan-2-yl)-4-(hydroxymethyl)pentane-1,5-diol 4f 
 
132 mg from 297 mg 7f, 35 % 2 steps, d.r. = 0.8:1; 
1
H NMR (400 MHz, CD3OD) δ major 
diastereomer: 7.47 – 7.42 (2H, Ar-H), 7.36 (1H, s, 11-H), 7.19 (2H, d, J = 8.3, Ar-H’), 6.28 
(1H, m, 10-H), 6.14 (1H, d, J = 3.0, 9-H), 4.13 (1H, dd, J = 10.6, 2.5, 2-H), 3.76 (2H, d, J = 
4.9, 6/7-H,H’), 3.43 ([1H, m, 7/6-H), 3.35 – 3.23 (1H, m, 7/6-H’) (obscured by solvent), 3.23 
– 3.10 (1H, m, 4-H), 2.33 (1H, ddd, J = 14.0, 10.6, 3.4, 3-H), 2.07 (1H, m, 3-H’), 1.90 – 1.79 
(1H, 5-H); minor  diastereomer: 7.47 – 7.42 (3H, 11-H, Ar-H), 7.06 (2H, d, J = 8.3, Ar-H’), 
6.35 (1H, m, 10-H), 6.20 (1H, d, J = 3.0, 9-H), 4.20 (1H, dd, J = 10.1, 4.7, 2-H), 3.70 (2H, d, 
J = 5.1, 6/7-H,H’), 3.43 (1H, m, 7/6-H), 3.23 – 3.10 (1H, m, 7/6-H’), 2.60 (1H, m, 3-H), 2.50 
(1H, ddd, J = 13.8, 10.3, 3.9, 4-H), 2.18 (1H, ddd, J = 13.1, 12.9, 4.7, 3-H’), 1.90 – 1.79 (1H, 
5-H); 
13
C NMR (100 MHz, CD3OD) δ 159.0, 157.2, 143.43, 143.40, 143.3, 142.8, 132.49, 
132.46, 131.8, 131.6, 121.05, 121.03, 111.07, 111.04, 108.1, 106.2, 66.7, 65.9, 62.2, 61.9, 
61.7, 61.6, 49.4 (obscured by CD3 septet), 41.3, 40.9, 39.8, 39.7; IR (thin film) νmax 3355 (br), 
2933, 2895, 1485, 1449, 1407, 1331, 1225, 1147, 1119, 1046, 1007, 964, 924, 875, 860, 845, 
808, 736, 669, 634, 597, 569, 541 cm
-1
; HRMS MNa
+
(C16H19O4NaBr) calcd 377.0364, found 
377.0369. 
 
 
1-(Furan-2-yl)-4-(hydroxymethyl)-3-(2,4,5-trimethoxyphenyl)pentane-1,5-diol 4g 
 
881 mg from 781 mg 7g, 89 % 2 steps, d.r. = 1:0.5; 
1
H NMR (300 MHz, CD3CN) δ major 
diastereomer: 7.40 (1H, dd, J = 1.8, 0.8, 11-H), 6.68 (1H, s(br), Ar-H), 6.59 (1H, s, Ar-H’), 
6.35 (1H, dd, J = 3.2, 1.8, 10-H), 6.17 (1H, d, J = 3.2, 9-H), 4.23 – 4.10 (1H, m, 2-H), 3.807 
(3H, s, Ar-OMe), 3.73 (3H, s, Ar-OMe’), 3.65 (3H, s, Ar-OMe’’), 3.82 – 3.60 (2H, m, 6-
H,H’), 3.45 – 3.13 (2H, m, 7-H,H’), 2.95 (1H, dd, J = 5.2, 5.2, 6-OH), 2.85 (1H, m, 4-H), 
2.67 (1H, dd, J = 5.3, 5.3, 7-OH), 2.35 (1H, ddd, J = 13.8, 9.7, 4.3, 3-H), 2.24 – 2.00 (1H, m, 
3-H’), 1.90 – 1.80 (1H, m, 5-H); minor  diastereomer: 7.35 (1H, dd, J = 1.8, 0.8, 11-H), 6.72 
(1H, s, Ar-H), 6.65 (1H, s, Ar-H’), 6.29 (1H, dd, J = 3.2, 1.8, 10-H), 6.13 (1H, d, J = 3.2, 9-
H), 4.23 – 4.10 (1H, m, 2-H), 3.811 (3H, s, Ar-OMe), 3.78 (3H, s, Ar-OMe’), 3.71 (3H, s, 
Ar-OMe’’), 3.82 – 3.60 (2H, m, 6-H,H’), 3.45 – 3.13 (3H, m, 4-H,7-H,H’), 3.03 (1H, dd, J = 
5.3, 5.3, 6-OH), 2.77 (1H, dd, J = 5.8, 5.3, 7-OH), 2.24 – 2.00 (2H, m, 3-H,H’), 1.90 – 1.80 
(1H, m, 5-H); 
13
C NMR (75 MHz, CD3CN) δ 159.1, 157.9, 153.1, 152.8, 149.1, 149.0, 144.3, 
144.1, 142.6, 123.12, 123.07, 110.9, 107.2, 105.8, 99.6, 99.1, 66.4, 65.8, 63.5, 63.1, 62.7, 
57.4, 57.0, 56.4, 47.73, 47.66, 38.9, 38.8, 30.8, 30.3; IR (thin film) νmax 3355 (br), 2933, 
1510, 1464, 1440, 1398, 1316, 1271, 1203, 1180, 1147, 1126, 1028, 865, 819, 741 cm
-1
; 
HRMS MNa
+
(C19H26O7Na) calcd 389.1576, found 389.1566. 
 
3-(4-bromophenyl)-4-(hydroxymethyl)-1-(5-methylfuran-2-yl)pentane-1,5-diol 4h 
 
95 mg from 271 mg 7h, 28 % 2 steps, d.r. = 1:0.6; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.39 (2H, d, J = 7.7, Ar-H), 6.96 (2H, d, J = 7.7, Ar-H’), 6.04 (1H, d, J = 2.7, 
9-H), 5.88 (1H, d, J = 2.7, 10-H), 4.30 (1H, dd, J = 8.1, 4.5, 2-H), 4.10 – 1.60 (11H, m, 6-
H,H’,7-H,H’,4-H,5-H,3-H,H’, 3 x OH), 2.23 (3H, s, 11-Me); minor diastereomer: 7.46 (2H, 
d, J = 7.4, Ar-H), 7.09 (2H, d, J = 7.4, Ar-H’), 5.96 (1H, d, J = 2.8, 9-H), 5.83 (1H, d, J = 2.8, 
10-H), 4.14 (1H, d, J = 10.1, 2-H), 4.10 – 1.60 (11H, m, 6-H,H’,7-H,H’,4-H,5-H,3-H,H’, 3 x 
OH), 2.20 (3H, s, 11-Me); 
13
C NMR (100 MHz, CD3CN) δ 154.9, 153.3, 152.0, 151.6, 141.7, 
141.6, 131.7, 131.6, 130.1, 129.9, 120.3, 120.2, 108.1, 106.3, 106.1, 106.0, 66.0, 65.0, 64.1, 
63.8, 46.5, 39.3, 38.5, 38.42, 38.36; IR (thin film) νmax 3316(br), 2920, 1486, 1435, 1408, 
1218, 1072, 1008, 962, 908, 819, 784, 727, 646, 554 cm
-1
; HRMS MNa
+
(C17H21O4BrNa) 
calcd 391.0521, found 391.0507. 
 4-(hydroxymethyl)-1-(5-methylfuran-2-yl)-3-phenylpentane-1,5-diol 4i 
 
108 mg from 223 mg 7i, 35 % 2 steps, d.r. = 1:0.5; 
1
H NMR (300 MHz, CDCl3) δ major  
diastereomer: 7.32 – 7.15 (3H, m, Ar-H), 7.10 – 7.04 (2H, m, Ar-H’), 6.04 (1H, d, J = 3.0, 9-
H), 5.87 (1H, dq, J = 3.0, 0.9, 10-H), 4.30 (1H, dd, J = 9.0, 5.3, 2-H), 3.97 – 3.79 (2H, m, 6-
H,H’), 3.57 – 3.28 (2H, m, 7-H,H’), 2.58 (1H, ddd, J = 10.5, 10.2, 4.1, 4-H), 2.43 (1H, ddd, J 
= 13.2, 9.0, 4.1, 3-H), 2.24 (3H, d, J = 0.9, 11-Me), 2.15 (1H, ddd, J = 13.2, 10.5, 5.3, 3-H’), 
2.04 – 1.75 (1H, m, 5-H); minor  diastereomer: 7.32 – 7.15 (5H, m, Ar-H), 5.95 (1H, d, J = 
3.0, 9-H), 5.82 (1H, dq, J = 3.0, 0.9, 10-H), 4.16 (1H, dd, J = 10.8, 1.9, 2-H), 3.97 – 3.79 (2H, 
m, 6-H,H’), 3.57 – 3.28 (2H, m, 7-H,H’), 3.15 (1H, m, 4-H), 2.33 (1H, m, 3-H), 2.20 (3H, d, 
J = 0.9, 11-Me), 2.04 – 1.75 (2H, m, 3-H’,5-H); 13C NMR (75 MHz, CDCl3) δ 155.2, 153.5, 
151.9, 151.4, 142.5, 128.6, 128.5, 128.3, 128.1, 126.6, 126.5, 108.0, 106.1, 106.0, 105.9, 
66.1, 65.0, 64.1, 63.9, 62.9, 46.7, 46.6, 40.1, 39.1, 38.54, 38.48, 13.6, 13.5; IR (thin film) νmax 
3307(br), 2921, 1452, 1219, 1019, 961, 909, 783, 763, 729, 701, 646, 587 cm
-1
; HRMS 
MNa
+
(C17H22O4Na) calcd 313.1416, found 313.1411. 
 
4-(hydroxymethyl)-1-(5-methylfuran-2-yl)-3-(p-tolyl)pentane-1,5-diol 4j 
 
134 mg from 287 mg 7j, 35 % 2 steps, d.r. = 1:0.6; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.07 – 7.05 (2H, m, Ar-H), 6.95 (2H, d, J = 8.0, Ar-H’), 6.02 (1H, d, J = 3.0, 9-
H), 5.86 (1H, dq, J = 3.0, 1.0, 10-H), 4.29 (1H, dd, J = 9.0, 5.4, 2-H), 3.95 – 3.73 (2H, m, 6-
H,H’), 3.55 – 3.25 (2H, m, 7-H,H’), 2.52 (1H, ddd, J = 10.4, 10.4, 4.1, 4-H), 2.45 – 2.05 (2H, 
m, 3-H,H’), 2.31 (3H, s, Ar-Me), 2.23 (3H, s, 11-Me), 2.02 – 1.75 (1H, m, 5-H): minor  
diastereomer: 7.07 – 7.05 (4H, m, Ar-H), 5.94 (1H, d, J = 3.1, b-9-H), 5.81 (1H, dq, J = 3.1, 
1.0, 10-H), 4.16 (1H, dd, J = 10.7, 1.6, 2-H), 3.95 – 3.73 (2H, m, 6-H,H’), 3.55 – 3.25 (2H, 
m, 7-H,H’), 3.09 (1H, m, 4-H), 2.45 – 2.05 (1H, m, 3-H), 2.31 (3H, s, Ar-Me), 2.20 (3H, s, 
11-Me), 2.02 – 1.75 (2H, m, 3-H’,5-H); 13C NMR (75 MHz, CDCl3) δ 155.3, 153.6, 151.8, 
151.3, 139.30, 139.28, 136.0, 135.9, 129.23, 129.17, 128.2, 127.9, 107.9, 106.03, 105.95, 
105.8, 66.1, 64.9, 64.0, 63.8, 62.7, 46.74, 46.66, 39.8, 38.7, 38.6, 38.5, 21.0, 13.5, 13.4; IR 
(thin film) νmax 3312(br), 2920, 1512, 1435, 1381, 1219, 1019, 962, 938, 909, 783, 727, 570 
cm
-1
; HRMS MNa
+
(C18H24O4Na) calcd 327.1572, found 327.1561. 
 
3-(4-chlorophenyl)-4-(hydroxymethyl)-1-(5-methylfuran-2-yl)pentane-1,5-diol 4k 
 
70 mg from 180 mg 7k, 30 % 2 steps, d.r. = 1:0.6; 
1
H NMR (300 MHz, CDCl3) δ major 
diastereomer: 7.23 (2H, d, J = 8.4, Ar-H), 7.00 (2H, d, J = 8.4, Ar-H), 6.03 (1H, d, J = 3.0, 9-
H), 5.87 (1H, dq, J = 3.0, 0.9, 10-H), 4.29 (1H, dd, J = 9.0, 5.2, 2-H), 3.97 – 3.78 (2H, m, 6-
H,H’), 3.60 – 2.80 (5H, m, 7-H,H’,3 x OH), 2.61 (1H, ddd, J = 10.3, 9.9, 4.1, 4-H), 2.47 – 
2.27 (1H, m, 3-H), 2.23 (3H, d, J = 0.9, 11-Me), 2.11 (1H, ddd, J = 13.5, 10.3, 5.2, 3-H’), 
1.95 – 1.70 (1H, m, 5-H); minor  diastereomer: 7.25 (2H, d, J = 8.4, Ar-H), 7.13 (2H, d, J = 
8.4, Ar-H), 5.95 (1H, d, J = 3.0, 9-H), 5.82 (1H, dq, J = 3.0, 0.9, 10-H), 4.12 (1H, dd, J = 
10.9, 1.9, 2-H), 3.97 – 3.78 (2H, m, 6-H,H’), 3.60 – 2.80 (6H, m , 4-H,7-H,H’,3 x OH), 2.47 
– 2.27 (1H, m, 3-H), 2.20 (3H, d, J = 0.9, 11-Me), 1.95 – 1.70 (2H, m, 3-H’,5-H); 13C NMR 
(75 MHz, CDCl3) δ 155.0, 153.3, 152.0, 151.5, 141.2, 141.1, 132.1, 129.7, 129.4, 128.7, 
128.6, 108.1, 106.3, 106.0, 105.9, 65.7, 64.9, 63.92, 63.86, 63.5, 62.7, 46.6, 46.5, 39.3, 38.5, 
38.4, 13.52, 13.45; IR (thin film) νmax 3316 (br), 2921, 1562, 1489, 1435, 1411, 1374, 1219, 
1089, 1012, 962, 820, 784, 723, 703, 553 cm
-1
; HRMS MNa
+
(C17H21O4ClNa) calcd 
347.1026, found 347.1019. 
  
General Procedure for the cyclisation of triols 4a-k to form trisubstituted 
tetrahydropyrans 5a-k 
 
Triol 4a-k (0.18 mmol) was dissolved in acetonitrile (5 mL). Quadrapure™ polymer 
supported sulfonic acid (20 mg, 5.0 mmol/g loading) was then added to the reaction mixture. 
The reaction mixture was stirred gently at room temperature for 24 hrs. Upon completion, the 
reaction mixture was filtered and the polymer beads washed three times with acetonitrile (5 
mL). The solution was then concentrated under reduced pressure.  The crude product was 
purified by column chromatography on silica gel (using a solvent gradient from petroleum 
ether to 1:1 petroleum ether – diethyl ether) to furnish the product 5a-k. Crystals of 5g for x-
ray diffraction were obtained by slow evaporation of an ethyl acetate solution from a glass 
vial plugged with cotton wool.  
 
(±)-((3S,4S,6S)-6-(furan-2-yl)-4-phenyltetrahydro-2H-pyran-3-yl)methanol 5a 
 
40 mg from 43 mg 4a, 99 %, 
1
H NMR (300 MHz, CDCl3) δ 7.40 – 7.20 (6H, m, 11-H, Ar-H), 
6.33 (1H, dd, J = 3.1, 1.8, 10-H), 6.28 (1H, d, J = 3.1, 9-H), 4.54 (1H, dd, J = 10.0, 3.7, 2-H), 
4.36 (1H, dd, J = 11.4, 4.4, 6-H-eq), 3.63 (1H, dd, J = 11.4, 11.3, 6-H-ax), 3.47 (1H, dd, J = 
11.0, 3.3, 7-H), 3.30 (1H, dd, J = 11.0, 6.8, 7-H’), 2.77 (1H, ddd, J = 11.0, 11.2, 6.1, 4-H), 
2.20 – 2.00 (3H, m, 3-H,H’, 5-H); 13C NMR (75 MHz, CDCl3) δ 154.2, 143.0, 142.2, 128.7, 
127.4, 126.8, 110.0, 106.5, 73.0, 71.2, 62.0, 43.8, 43.2, 37.5; IR (thin film) νmax 3407, 2920, 
1720, 1601, 1494, 1452, 1378, 1336, 1278, 1228, 1174, 1147, 1128, 1042, 1011, 909, 884, 
847, 813, 760, 729, 700 cm
-1
; HRMS MNa
+
(C16H18O3Na) calcd 281.1154, found 281.1143. 
 
(±)-((3S,4S,6S)-4-(4-chlorophenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-yl)methanol 5b 
 
61 mg from 68 mg 4b, 95 %, 
1
H NMR (300 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.7, 0.7, 11-H), 
7.31 (2H, d, J = 8.5, Ar-H), 7.20 (2H, d, J = 8.5, Ar-H’), 6.33 (1H, dd, J = 3.2, 1.7, 10-H), 
6.28 (1H, d, J = 3.2, 9-H), 4.53 (1H, m, 2-H), 4.35 (1H, dd, J = 11.4, 4.4, 6-H-eq), 3.64 (1H, 
dd, J = 11.4, 11.3, 6-H-ax), 3.47 (1H, dd, J = 11.0, 3.2, 7-H), 3.31 (1H, dd, J = 11.0, 6.7, 7-
H’), 2.79 (1H, ddd, J = 11.1, 8.3, 5.8, 4-H), 2.15 – 2.01 (3H, m, 3-H,H’, 5-H); 13C NMR (75 
MHz, CDCl3) δ 154.0, 142.3, 141.6, 132.4, 128.9, 128.8, 110.1, 106.6, 73.0, 71.1, 61.8, 43.2, 
43.1, 37.5; IR (thin film) νmax 3398 (br), 2919, 2855, 1491, 1411, 1338, 1266, 1227, 1173, 
1147, 1128, 1087, 1073, 1044, 1012, 924, 884, 826, 735, 702 cm
-1
; HRMS 
MNa
+
(C16H17O3ClNa) calcd 315.0764, found 315.0777. 
 
(±)-((3S,4S,6S)-6-(furan-2-yl)-4-(4-methoxyphenyl)tetrahydro-2H-pyran-3-yl)methanol 
5c 
 
60 mg from 73 mg 4c, 87 %,
1
H NMR (300 MHz, CDCl3) δ 7.38 (1H, dd, J = 1.7, 0.7, 11-H), 
7.19 (2H, d, J = 8.7, Ar-H), 6.88 (2H, d, J = 8.7, Ar-H’), 6.33 (1H, dd, J = 3.2, 1.7, 10-H), 
6.28 (1H, d, J = 3.2, 9-H), 4.53 (1H, m, 2-H), 4.34 (1H, dd, J = 11.3, 4.4, 6-H-eq), 3.79 (3H, 
s, OMe), 3.62 (1H, dd, J = 11.3, 11.3, 6-H’-ax), 3.48 (1H, dd, J = 11.0, 3.3, 7-H), 3.32 (1H, 
dd, J = 11.0, 6.7, 7-H’), 2.72 (1H, ddd, J = 11.0, 8.3, 5.6, 4-H), 2.15 – 2.02 (3H, m, 3-H,H’, 
5-H); 
13
C NMR (75 MHz, CDCl3) δ 158.4, 154.3, 142.2, 135.2, 128.3, 114.2, 110.1, 106.4, 
73.2, 71.2, 62.2, 55.3, 43.6, 43.2, 37.8; IR (thin film) νmax 3390 (br), 2937, 2916, 2835, 1610, 
1511, 1462, 1304, 1248, 1178, 1129, 1148, 1129,1108, 1073, 1036, 1011, 910, 830, 803, 732, 
632, 600, 530, 515 cm
-1
; HRMS MH
+
(C17H21O4) calcd 289.1440, found 289.1433. 
 
(±)-((3S,4S,6S)-6-(furan-2-yl)-4-(p-tolyl)tetrahydro-2H-pyran-3-yl)methanol 5d 
 
72 mg from 86 mg, 4d, 89 %, 
1
H NMR (300 MHz, CDCl3) δ 7.38 (1H, dd, J = 1.8, 0.8, 11-
H), 7.17 – 7.13 (4H, m, Ar-H), 6.33 (1H, dd, J = 3.2, 1.8, 10-H), 6.27 (1H, d, J = 3.2, 9-H), 
4.54 (1H, dd, J = 9.4, 4.3, 2-H), 4.35 (1H, dd, J = 11.4, 4.4, 6-H-eq), 3.62 (1H, dd, J = 11.4, 
11.3, 6-H-ax), 3.48 (1H, dd, J = 11.0, 3.4, 7-H), 3.32 (1H, dd, J = 11.0, 6.7, 7-H’), 2.73 (1H, 
m, 4-H), 2.34 (3H, s, Ar-Me), 2.17 – 2.00 (3H, m, 3-H,H’, 5-H); 13C NMR (75 MHz, CDCl3) 
δ 154.3, 142.2, 140.1, 136.4, 129.5, 127.3, 110.1, 106.4, 73.1, 71.2, 62.3, 43.6, 43.4, 37.7, 
21.0; IR (thin film) νmax 3410 (br), 2918, 2859, 1514, 1458, 1435, 1377, 1353, 1337, 1227, 
1172, 1147, 1128, 1110, 1072, 1040, 1009, 942, 922, 901, 883, 851, 815, 732, 668, 599, 586, 
545, 507 cm
-1
; HRMS MNa
+
(C17H20O3Na) calcd 295.1310, found 295.1320. 
 
(±)-((3S,4S,6S)-4-(3,4-dimethoxyphenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-
yl)methanol 5e 
 
213 mg from 252 mg 4e, 89 %, 
1
H NMR (300 MHz, CDCl3) δ 7.39 (1H, dd, J = 1.7, 0.7, 11-
H), 6.83 (3H, m, Ar-H), 6.34 (1H, dd, J = 3.2, 1.7, 10-H), 6.29 (1H, d, J = 3.2, 9-H), 4.53 
(1H, m, 2-H), 4.35 (1H, dd, J = 11.4, 4.4, 6-H-eq), 3.89 (3H, s, OMe), 3.87 (3H, s, OMe), 
3.63 (1H, dd, J = 11.4, 11.3, 6-H-ax), 3.51 (1H, ddd, J = 11.1, 3.9, 3.9, 7-H), 3.35 (1H, ddd, J 
= 11.1, 6.3, 6.3, 7-H’), 2.73 (1H, ddd, J = 11.0, 8.0, 6.3, 4-H), 2.16 – 2.01 (3H, m, 3-H,H’, 5-
H); 
13
C NMR (75 MHz, CDCl3) δ 154.3, 149.1, 147.8, 142.3, 135.7, 119.4, 111.3, 110.2, 
110.1, 106.5, 73.2, 71.2, 62.3, 55.89, 55.86, 43.7, 43.6, 37.8; IR (thin film) νmax 3445 (br), 
2947, 2923, 2873, 2836, 1591, 1516, 1463, 1452, 1440, 1377, 1351, 1318, 1309, 1261, 1241, 
1231, 1181, 1174, 1157, 1174, 1144, 1121, 1077, 1060, 1041, 1026, 1012, 952, 899, 881, 
809, 767, 738, 701 cm
-1
; HRMS MH
+
(C18H23O5) calcd 319.1545, found 319.1530. 
 
(±)-((3S,4S,6S)-4-(4-bromophenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-yl)methanol 5f 
 
75 mg from 92 mg 4f, 86 %, 
1
H NMR (300 MHz, CDCl3) δ 7.46 (2H, d, J = 8.4, Ar-H), 7.38 
(1H, dd, J = 1.8, 0.7, 11-H), 7.14 (2H, dd, J = 8.4, Ar-H’), 6.33 (1H, dd, J = 3.3, 1.8, 10-H), 
6.28 (1H, d, J = 3.3, 9-H), 4.53 (1H, m, 2-H), 4.35 (1H, dd, J = 11.4, 4.4, 6-H), 3.64 (1H, dd, 
J = 11.4, 11.3, 6-H’), 3.47 (1H, dd, J = 11.0, 3.1, 7-H), 3.31 (1H, dd, J = 11.0, 6.7, 7-H’), 
2.79 (1H, ddd, J = 11.0, 8.2, 6.0, 4-H), 2.14 – 1.98 (3H, m, 3-H,H’, 5-H); 13C NMR (75 MHz, 
CDCl3) δ 153.9, 142.2, 142.1, 131.8, 129.1, 120.4, 110.1, 106.6, 72.9, 71.0, 61.6, 43.1, 43.0, 
37.3; IR (thin film) νmax 3391 (br), 2919, 1488, 1408, 1338, 1148, 1128, 1072, 1044, 1009, 
908, 884, 822, 731, 702, 648, 632, 599, 536 cm
-1
; HRMS MNa
+
(C16H17O3BrNa) calcd 
359.0259, found 359.0243. 
 
 
(±)-((3S,4S,6S)-6-(furan-2-yl)-4-(2,4,5-trimethoxyphenyl)tetrahydro-2H-pyran-3-
yl)methanol 5g 
 
188 mg from 207 mg 4g, 96 %, 
1
H NMR (300 MHz, CDCl3) δ 7.40 (1H, dd, J = 1.8, 0.8, 11-
H), 6.79 (1H, s, Ar-H), 6.55 (1H, s, Ar-H), 6.35 (1H, dd, J = 3.2, 1.8, 10-H), 6.31 (1H, d, J = 
3.2, 9-H), 4.57 (1H, dd, J = 11.2, 2.1, 2-H), 4.24 (1H, dd, J = 11.5, 4.3, 6-H-eq), 3.90 (3H, s, 
Ar-OMe), 3.86 (3H, s, Ar-OMe’), 3.85 (3H, s, Ar-OMe’’), 3.83 (1H, m, 6-H-ax) (obscured. 
by OMe), 3.44 – 3.26 (3H, m, 7-H,H’,4-H), 2.28 – 2.14 (2H, m, 3-H,5-H), 2.01 (1H, ddd, J = 
13.1, 3.6, 2.1, 3-H’); 13C NMR (75 MHz, CDCl3) δ 154.4, 150.7, 148.0, 143.8, 142.2, 122.3, 
110.1, 106.4, 97.5, 73.2, 71.3, 61.7, 56.9, 56.5, 56.1, 44.5, 35.8, 30.3; IR (thin film) νmax 3447 
(br), 2924, 2851, 1509, 1463, 1440, 1399, 1318, 1266, 1204, 1178, 1075, 1034, 1012, 863, 
816, 734, 701 cm
-1
; HRMS MNa
+
(C19H24O6Na) calcd 371.1471, found 371.1477. 
 
(±)-((3S,4S,6S)-4-(4-bromophenyl)-6-(5-methylfuran-2-yl)tetrahydro-2H-pyran-3-
yl)methanol 5h 
 
48 mg from 80 mg 4h, 63 %, 
1
H NMR (300 MHz, CDCl3) δ 7.45 (2H, d, J = 8.4, Ar-H), 7.14 
(2H, dd, J = 8.4, Ar-H’), 6.15 (1H, d, J = 3.1, 9-H), 5.90 (1H, dd, J = 3.1, 0.9, 10-H), 4.46 
(1H, dd, J = 10.3, 3.3, 2-H), 4.34 (1H, dd, J = 11.4, 4.4, 6-H), 3.63 (1H, dd, J = 11.4, 11.3, 6-
H’), 3.46 (1H, dd, J = 10.9, 3.1, 7-H), 3.29 (1H, dd, J = 10.9, 6.7, 7-H’), 2.76 (1H, ddd, J = 
11.2, 11.2, 6.0, 4-H), 2.28 (3H, s, 11-Me), 2.13 – 1.98 (3H, m, 3-H,H’, 5-H); 13C NMR (75 
MHz, CDCl3) δ 152.0, 151.9, 142.1, 131.7, 129.1, 120.2, 107.5, 105.9, 72.8, 70.9, 61.4, 43.1, 
42.9, 37.2, 13.4; IR (thin film) νmax 3419 (br), 2945, 2919, 2862, 1565, 1488, 1408, 1378, 
1337, 1223, 1131, 1103, 1072, 1050, 1009, 850, 822, 785, 718 cm
-1
; HRMS 
MNa
+
(C17H19O3BrNa) calcd 373.0410, found 373.0401. 
 
 
  
 
 
(±)-((3S,4S,6S)-6-(5-methylfuran-2-yl)-4-phenyltetrahydro-2H-pyran-3-yl)methanol 5i 
 
62 mg from 79 mg 4i, 84 %, 
1
H NMR (300 MHz, CDCl3) δ 7.38 – 7.20 (5H, m, Ar-H), 6.15 
(1H, d, J = 3.1, 9-H), 5.90 (1H, dq, J = 3.1, 0.9, 10-H), 4.48 (1H, dd, J = 10.8, 2.9, 2-H), 4.36 
(1H, dd, J = 11.4, 4.3, 6-H-eq), 3.63 (1H, dd, J = 11.4, 11.3, 6-H-ax), 3.47 (1H, m, 7-H), 3.31 
(1H, m, 7-H’), 2.76 (1H, ddd, J = 11.4, 11.4, 4.8, 4-H), 2.29 (3H, s, 11-Me), 2.22 – 2.00 (3H, 
m, 3-H,H’, 5-H); 13C NMR (75 MHz, CDCl3) δ 152.4, 152.1, 143.2, 128.8, 127.4, 126.8, 
107.5, 106.0, 73.1, 71.2, 62.2, 44.0, 43.3, 37.4, 13.6; IR (thin film) νmax 3402 (br), 2942, 
2918, 2853, 1565, 1494, 1452, 1435, 1378, 1335, 1221, 1129, 1067, 1048, 1018, 949, 923, 
782, 760, 700, 636, 618, 569, 554, 533 cm
-1
; HRMS MNa
+
(C17H20O3Na) calcd 295.1310, 
found 295.1309. 
 
(±)-((3S,4S,6S)-6-(5-methylfuran-2-yl)-4-(p-tolyl)tetrahydro-2H-pyran-3-yl)methanol 5j 
 
68 mg from 96 mg 4j, 75 %, 
1
H NMR (300 MHz, CDCl3) δ 7.17 – 7.09 (4H, m, Ar-H), 6.15 
(1H, d, J = 3.1, 9-H), 5.90 (1H, dq, J = 3.1, 0.9, 10-H), 4.47 (1H, dd, J = 10.7, 2.9, 2-H), 4.34 
(1H, dd, J = 11.4, 4.4, 6-H-eq), 3.60 (1H, dd, J = 11.4, 11.3, 6-H-ax), 3.46 (1H, dd, J = 11.1, 
3.4, 7-H), 3.29 (1H, dd, J = 11.1, 6.8, 7-H’), 2.71 (1H, ddd, J = 11.4, 11.4, 4.8, 4-H), 2.34 
(3H, s, Ar-Me), 2.28 (3H, d, J = 0.9, 11-Me), 2.20 – 1.97 (3H, m, 3-H,H’, 5-H); 13C NMR 
(75 MHz, CDCl3) δ 152.4, 152.0, 140.1, 136.3, 129.4, 127.2, 107.4, 105.9, 73.1, 71.1, 62.2, 
43.5, 43.3, 37.5, 21.0, 13.5; IR (thin film) νmax 3402 (br), 2943, 2918, 2857, 1565, 1514, 
1435, 1378, 1335, 1305, 1280, 1220, 1169, 1129, 1109, 1074, 1048, 1018, 942, 922, 898, 
882, 852, 816, 782, 756, 722, 636, 587, 549, 508 cm
-1
; HRMS MH
+
 (C18H23O3) calcd 
287.1647, found 287.1637. 
 
(±)-((3S,4S,6S)-4-(4-chlorophenyl)-6-(5-methylfuran-2-yl)tetrahydro-2H-pyran-3-
yl)methanol 5k 
 
52 mg from 63 mg 4k, 87 %, 
1
H NMR (300 MHz, CDCl3) δ 7.31 (2H, d, J = 8.5, Ar-H), 7.20 
(2H, d, J = 8.5, Ar-H), 6.15 (1H, d, J = 3.1, 9-H), 5.90 (1H, dq, J = 3.1, 0.9, 10-H), 4.47 (1H, 
dd, J = 10.4, 3.2, 2-H), 4.35 (1H, dd, J = 11.4, 4.4, 6-H-eq), 3.63 (1H, dd, J = 11.4, 11.3, 6-H-
ax), 3.47 (1H, dd, J = 11.0, 3.3, 7-H), 3.31 (1H, dd, J = 11.0, 6.7, 7-H’), 2.78 (1H, ddd, J = 
11.3, 11.3, 5.4, 4-H), 2.28 (3H, d, J = 0.9, 11-Me), 2.15 – 2.00 (3H, m, 3-H,H’, 5-H); 13C 
NMR (75 MHz, CDCl3) δ 152.2, 152.1, 141.7, 132.4, 128.9, 128.8, 107.6, 106.0, 73.0, 71.1, 
61.9, 43.3, 43.2, 37.4, 13.6; IR (thin film) νmax 3391 (br), 2945, 2919, 2855, 1564, 1491, 
1453, 1435, 1411, 1378, 1336, 1297, 1221, 1129, 1085, 1073, 1048, 1013, 942, 850, 825, 
784, 730, 692, 646, 634, 573, 543, 530 cm
-1
; HRMS MH
+
(C17H20ClO3) calcd 307.1101, 
found 307.1069. 
 
Procedure for the silylation of the triol anti-4b to form mono TBDPS ethers 11a and 11b 
 
Anti-4b (100 mg, 0.32 mmol, 1 equiv) was dissolved in 2.5 mL anhydrous THF under dry 
nitrogen. DMAP (391 mg, 3.2 mmol, 10 equiv) was added at room temperature and the 
mixture was stirred until the DMAP dissolved. A few small grains of calcium hydride (from a 
freshly ground chunk) were added (causing effervescence). The mixture was stirred at room 
temperature under nitrogen for 1 hr, after which the effervescence had stopped. tert-
Butyldiphenylsilyl chloride (83 μL, 88 mg, 0.32 mmol, 1 equiv.) was added dropwise. The 
reaction was stirred at room temperature for 10 minutes. TLC indicated that significant 
starting material was still present. Another quantity of the silyl chloride (25 μL) was added 
and stirring continued for another 10 minutes. TLC indicated that only a slight amount of 
starting material remained and that the mono-silylated products were the main components (a 
small amount of bis-silylated product may also have formed). After the reaction flask had 
been placed in an ice/water cold bath, the reaction was diluted by the addition of 5 mL of 
diethyl ether and was quenched by the slow dropwise addition of distilled water (3 mL) 
which was accompanied initially by effervescence. The mixture was diluted by the addition 
of a further 20 mL of diethyl ether and 20 mL of water, followed by vigorous 
shaking/separation in a separating funnel. The aqueous layer was extracted with diethyl ether 
(3 x 10 mL), washed with water (20 mL), brine (20 mL) and dried over magnesium sulfate. 
Following filtration, the solvent was removed under reduced pressure. The crude material 
was purified by column chromatography on silica gel (Merck 9385 grade) using a slow 
gradient from dichloromethane to 9:1 dichloromethane : diethyl ether. Following removal of 
solvent under reduced pressure, two clean monosilylated fractions were obtained: 11a (62 
mg, 35 %) and 11b (59 mg, 34 %).  
 
(±)-(1S,3S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-chlorophenyl)-1-(furan-2-
yl)pentane-1,5-diol 11a 
 
1
H NMR (300 MHz, CD3CN) δ 7.52 – 7.02 (15H, m, 11-H, Ar-H, Si-Ar-H), 6.29 (1H, dd, J = 
3.2, 1.9, 10-H), 6.12 (1H, ddd, J = 3.2, 0.7, 0.7, 9-H), 4.04 (1H, ddd, J = 10.7, 5.5, 2.8, 2-H), 
3.90 – 3.74 (2H, m, 6-H,H’), 3.48 (1H, dd, J = 10.3, 4.3, 7-H), 3.42 (1H, dd, J = 10.3, 6.4, 7-
H’), 3.24 (1H, d, J = 5.5, 2-OH), 3.12 (1H, m, 4-H), 2.78 (1H, dd, J = 5.2, 5.2, 6-OH), 2.35 – 
2.25 (1H, m, 3-H), 1.97 – 1.85 (2H, m, 3-H’, 5-H), 0.99 (9H, s, Si-tBu); 13C NMR (75 MHz, 
CD3CN) δ 159.0, 142.9, 142.5, 136.3, 136.2, 134.3, 134.2, 131.2, 130.64, 130.61, 129.8, 
129.1, 128.62, 128.58, 111.0, 105.9, 65.1, 63.5, 60.9, 48.9, 40.1, 40.0, 27.1, 19.6; IR (thin 
film) νmax 3345 (br), 2930, 2857, 1489, 1472, 1390, 1361, 1261, 1145, 1106, 1088, 1013, 970, 
940, 858, 822, 738 cm
-1
; HRMS MNa
+
(C32H37O4SiClNa) calcd 571.2047, found 571.2019. 
 
(±)-(1S,3S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-chlorophenyl)-1-(furan-2-
yl)pentane-1,5-diol 11b 
 
1
H NMR (300 MHz, CD3CN) δ 7.75  - 7.67 (4H, m, Si-Ar-H), 7.50 – 7.20 (11H, m, Si-Ar-H’, 
Ar-H, 11-H), 6.30 (1H, dd, J = 3.2, 1.9, 10-H), 6.09 (1H, ddd, J = 3.2, 0.6, 0.6, 9-H), 4.08 
(1H, ddd, J = 10.5, 5.3, 3.0, 2-H), 3.81 (1H, dd, J = 10.1, 4.9, 7-H), 3.76 (1H, dd, J = 10.1, 
4.8, 7-H’), 3.45 (1H, m, 6-H), 3.35 – 3.21 (2H, m, 4-H, 6-H’), 3.20 (1H, d, J = 5.3, 2-OH), 
2.55 (1H, dd, J = 5.5, 4.8, 6-OH), 2.28 – 2.19 (1H, m, 3-H), 2.02 – 1.85 (1H, m, 3-H’, 5-H), 
1.05 (9H, s, Si-
t
Bu); 
13
C NMR (75 MHz, CD3CN) δ 159.0, 142.8, 142.5, 136.5, 136.4, 
134.44, 134.40, 131.3, 130.71, 130.70, 129.8, 129.1, 128.71, 128.68, 111.0, 105.9, 65.1, 63.1, 
61.3, 49.2, 40.2, 39.3, 27.2, 19.7; IR (thin film) νmax 3365 (br), 2930, 2857, 1490, 1472, 1390, 
1361, 1262, 1144, 1106, 1088, 1013, 940, 884, 822, 738 cm
-1
; HRMS 
MNa
+
(C32H37O4SiClNa) calcd 571.2047, found 571.2026. 
 
 
  
 
Procedure for the silylation of syn-4b to form 11c and 11d 
Syn-4b (100 mg, 0.32 mmol, 1 equiv) was dissolved in 5 mL dichloromethane (which had 
previously been dried by stirring over calcium hydride under nitrogen, then allowed to settle) 
under dry nitrogen. DMAP (195 mg, 1.60 mmol, 5 equiv) was added at room temperature and 
the mixture was stirred until the DMAP dissolved. A few small grains of calcium hydride 
(from a freshly ground chunk) were added (causing effervescence). The mixture was stirred 
at room temperature under nitrogen for 1 hr, after which the effervescence had stopped. tert-
Butyldiphenylsilyl chloride (83 µL, 88 mg, 0.32 mmol, 1 equiv.) was added dropwise. The 
reaction was stirred at room temperature for 10 minutes. TLC indicated that only a slight 
amount of starting material remained and that the mono-silylated products were the main 
components (a small amount of bis-silylated product may also have formed). After the 
reaction flask was placed in an ice/water bath, the reaction was diluted by the addition of 5 
mL of diethyl ether and was quenched by the slow dropwise addition of distilled water (3 
mL) which was accompanied initially by effervescence. The mixture was diluted by the 
addition of a further 20 mL of diethyl ether and 20 mL of water, followed by vigorous 
shaking/separation in a separating funnel. The aqueous layer was extracted with diethyl ether 
(3 x 10 mL), washed with water (20 mL), brine (20 mL) and dried over magnesium sulfate. 
Following filtration, the solvent was removed under reduced pressure. The crude material 
was purified by column chromatography on silica gel (Merck 9385 grade) using a slow 
gradient from dichloromethane to 9:1 dichloromethane : diethyl ether. Following removal of 
solvent under reduced pressure, two clean monosilylated fractions were obtained: 11c (68 
mg, 39 %) and 11d (67 mg, 38 %).  
 
 
(±)-(1R,3S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-chlorophenyl)-1-(furan-2-
yl)pentane-1,5-diol 11c 
 
1
H NMR (400 MHz, CDCl3) δ 7.58 – 7.28 (11H, m, Si-Ar-H, 11-H), 7.14 (2H, d, J = 8.0, Ar-
H), 6.87 (2H, d, J = 8.0, Ar-H’), 6.34 (1H, s (br), 10-H), 6.22 (1H, s (br), 9-H), 4.30 (1H, m, 
2-H), 3.99 (1H, m, 6-H), 3.91 (1H, m, 6-H’), 3.51 (1H, d, J = 10.0, 7-H), 3.34 (1H, dd, J = 
10.0, 5.7, 7-H’), 2.66 (1H, dd, J = 10.1, 10.1, 4-H), 2.58 (1H, dd, J = 5.3, 5.3, 6-OH), 2.48 
(1H, m, 3-H), 2.19 – 2.04 (2H, m, 2-OH, 3-H’), 1.86 (1H, m, 5-H), 0.99 (9H, s, Si-tBu); 13C 
NMR (100 MHz, CD3CN) δ 155.5, 142.2, 141.2, 135.4, 132.7, 132.6, 132.1, 129.83, 129.77, 
129.4, 128.5, 127.74, 127.66, 110.1, 107.1, 66.2, 64.9, 63.5, 47.0, 39.4, 38.8, 26.8, 19.0; IR 
(thin film) νmax 3364 (br), 2930, 1490, 1472, 1428, 1393, 1261, 1148, 1111, 1066, 1013, 823, 
738 cm
-1
; HRMS MNa
+
(C32H37O4SiClNa) calcd 571.2047, found 571.2059. 
 
(±)-(1R,3S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-chlorophenyl)-1-(furan-2-
yl)pentane-1,5-diol 11d 
 
1
H NMR (300 MHz, CD3CN) δ 7.73 – 7.65 (4H, m, Si-Ar-H), 7.49 – 7.34 (7H, m, Si-Ar-H’, 
11-H), 7.27 (2H, d, J = 8.5, Ar-H), 7.09 (2H, d, J = 8.5, Ar-H’), 6.31 (1H, dd, J = 3.2, 1.9, 
10-H), 6.10 (1H, d, J = 3.2, 9-H), 4.18 (1H, dd, J = 9.7, 5.0, 2-H), 3.79 (1H, dd, J = 10.3, 5.0, 
7-H), 3.64 (1H, dd, J = 10.3, 5.6, 7-H’), 3.40 (1H, dd, J = 10.5, 4.2, 6-H), 3.27 (1H, s (br), 2-
OH), 3.16 (1H, dd, J = 10.5, 7.9, 6-H’), 2.75 (1H, ddd, J = 11.5, 7.5, 4.2, 4-H), 2.50 (1H, s 
(br), 6-OH), 2.37 (1H, ddd, J = 13.5, 9.7, 4.2, 3-H), 2.15 (1H, ddd, J = 13.5, 11.5, 5.0, 3-H’), 
1.84 (1H, m, 5-H), 1.04 (9H, s, Si-
t
Bu); 
13
C NMR (100 MHz, CDCl3) δ 157.3, 142.9, 142.5, 
136.4, 134.43, 134.40, 132.2, 131.1, 130.72, 130.69, 129.0, 128.70, 128.67, 110.9, 107.5, 
66.3, 63.1, 60.9, 49.3, 40.5, 39.6, 27.3, 19.8; IR (thin film) νmax 3365 (br), 2930, 2857, 1490, 
1472, 1427, 1390, 1361, 1148, 1111, 1090, 1012, 941, 909, 884, 823, 778, 736 cm
-1
; HRMS 
MNa
+
(C32H37O4SiClNa) calcd 571.2047, found 571.2036. 
 
General Procedure for the cyclization of silyl tetrahydopyrans 11a-d to form silyl 
tetrahydropyrans 12a-d.  
These cyclisations were performed following the procedure outlined above for the cyclisation 
of triols 4a-k. The reaction time was limited to 3 hours. 11a (43 mg) provided 41 mg of 
12a/b (98 %). 11b (53 mg) provided 48 mg of 12c/d (94%). 11c (47 mg) provided 45 mg of 
12a/b (99%). 11d (59 mg) provided 55 mg of 12c/d (96%).  
 
(±)-tert-butyl(((3R,4S,6S)-4-(4-chlorophenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-
yl)methoxy)diphenylsilane 12a 
 
1
H NMR (400 MHz, CD3CN) δ 7.54 – 7.02 (11H, m, 11-H, Ar-H, Si-Ar-H), 6.32 (1H, dd, J = 
3.1, 1.7, 10-H), 6.27 (1H, d, J = 3.1, 9-H), 4.54 (1H, dd, J = 10.3, 3.2, 2-H), 4.37 (1H, dd, J = 
11.4, 4.3, 6-H), 3.73 (1H, dd, J = 11.4, 11.2, 6-H’), 3.40 (1H, dd, J = 10.7, 2.7, 7-H), 3.34 
(1H, dd, J = 10.7, 6.5, 7-H’), 2.86 (1H, ddd, J = 11.3, 11.2, 5.1, 4-H), 2.13 – 1.94 (3H, m, 3-
H,H’, 5-H), 1.02 (9H, s, Si-tBu) (selected peaks for 12b: 6.42 (1H, dd, J = 3.2, 1.7, 10-H), 
6.38 (1H, d, J = 3.2, 9-H), 5.08 (1H, d, J = 4.8, 2-H); 
13
C NMR (100 MHz, CD3CN) δ 155.8, 
143.4, 143.1, 136.3, 136.2, 134.1, 134.0, 132.4, 130.74, 130.69, 130.2, 129.4, 128.7, 128.6, 
111.1, 107.3, 73.6, 71.8, 63.5, 44.0, 43.5, 38.4, 27.1, 19.6; IR (thin film) νmax 2929, 2856, 
1589, 1491, 1471, 1427, 1389, 1149, 1110, 1076, 1046, 1013, 926, 823, 850, 738, 700 cm
-1
; 
HRMS MNa
+
(C32H35O3ClSiNa) calcd 553.1942, found 553.1937. 
(±)-tert-butyl(((3S,4S,6S)-4-(4-chlorophenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-
yl)methoxy)diphenylsilane 12c 
 
1
H NMR (300 MHz, CDCl3) δ 7.52 – 6.78 (15H, Ar-H, Si-Ar-H, 11-H), 6.36 (1H, dd, J = 3.2, 
1.9, 10-H), 6.31 (1H, d, J = 3.2, 9-H), 4.60 (1H, m, 2-H), 4.55 (1H, dd, J = 11.4, 2.3, 6-H), 
3.95 (1H, dd, J = 10.2, 10.2, 7-H), 3.93 (1H, m, 6-H’), 3.30 – 3.13 (2H, m, 4-H, 7-H’), 2.22 – 
1.84 (3H, m, 3-H,H’, 5-H), 0.94 (9H, s, Si-tBu); selected peak for 12d: 5.11, (H, dd, J = 4.9, 
4.9, 2-H); 
13
C NMR (100 MHz, CD3CN) δ 156.2, 143.1, 142.6, 136.2, 136.1, 134.5, 134.3, 
132.3, 130.62, 130.60, 129.5, 129.1, 128.9, 128.6, 111.2, 107.3, 73.8, 69.2, 60.3, 43.3, 41.8, 
29.9, 27.0, 19.5; IR (thin film) νmax 3070, 2929, 2889, 2856, 1589, 1492, 1472, 1428, 1390, 
1362, 1253, 1152, 1111, 1091, 1013, 997, 924, 885, 860, 822, 797, 769, 739, 702 cm
-1
; 
HRMS MNa
+
(C32H35O3SiClNa) calcd 553.1942, found 553.1952. 
 
General Procedure for the desilylation of silyl tetrahydopyrans 12a-d to form 
tetrahydropyrans 5b 
Silyl-tetrahydropyrans 12a,b (30 mg, 0.056 mmol, 1 equiv) were dissolved in tetrahydrofuran 
(5 mL). Tetrabutylammonium fluoride trihydrate (177 mg, 0.56 mmol, 10 equiv) was added 
and the mixture was stirred at room temperature under dry nitrogen for 36 hr, after which 
time TLC analysis indicated that the reaction had gone to completion. The mixture was 
partitioned between water (20 mL) and diethyl ether (20 mL). The aqueous layer was washed 
with diethyl ether (3 x 10 mL). The combined organic layers were washed with water (10 
mL), brine (10 mL) and dried over magnesium sulfate. Following the removal of solvent 
under reduced pressure, NMR spectra of the crude material were obtained. The crude 
material was then purified by column chromatography on silica gel to afford a mixture of 
syn,anti-5b and anti,anti-5b (16 mg, 98 %). NMR analysis indicated that no significant 
change in d.r. had occurred during the deprotection step, or during the chromatographic 
purification. Similarly, 37 mg of 12c,d provided 19 mg (92 %) of syn,syn-5b and anti,syn-
5b.  
 
(±)-((3R,4S,6S)-4-(4-chlorophenyl)-6-(furan-2-yl)tetrahydro-2H-pyran-3-yl)methanol 
syn,syn-5b 
 
1
H NMR (400 MHz, CD3CN) δ 7.47 (1H, s, 11-H), 7.36 (2H, d, J = 8.5, Ar-H), 7.27 (2H, d, J 
= 8.5, Ar-H’), 6.40 (2H, m, 10-H, 9-H), 4.53 (1H, dd, J = 11.5, 2.2, 2-H), 4.25 (1H, d, J = 
11.3, 6-H), 3.75 (1H, d, J = 11.3, 6-H’), 3.65 (1H, ddd, J = 10.4, 10.4, 6.3, 7-H), 3.30 (1H, 
ddd, J = 13.1, 4.0, 4.0, 4-H), 3.06 (1H, m, 7-H’), 2.48 (1H, dd, J = 6.3, 4.5, 7-OH), 2.23 (1H, 
m, 3-H), 1.93 – 1.85 (2H, m, 3-H’, 5-H); selected peaks for anti,syn-5b: 5.09 (1H, dd, J = 
4.4, 4.4, 2-H), 3.87 (1H, dd, J = 11.7, 3.7, 6/7-H), 3.42 (1H, ddd, J = 9.2, 4.4, 4.4, 4-H); 
13
C 
NMR (100 MHz, CD3CN) δ 156.2, 143.1, 132.4, 129.8, 129.2, 111.2, 107.4, 73.8, 69.3, 58.1, 
43.2, 42.3, 30.1; IR (thin film) νmax 3397 (br), 2956, 1492, 1449, 1408, 1368, 1344, 1253, 
1228, 1173, 1150, 1068, 1093, 1045, 1013, 990, 971, 885, 857, 825, 740, 701 cm
-1
; HRMS 
MNa
+
(C16H17O3ClNa) calcd 315.0764, found 315.0772. 
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